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GENERAL INTRODUCTION 
Introduction 
Fatty liver (i.e.. hepatic lipidosis) is recognized as a major metabolic disease that affects 
up to 50% of dairy cows in early lactation (Gerloff et al., 1986b; Johannsen et al., 1993; 
Jomtsma et al.. 2001 ; Reid, 1980; Reid and Roberts, 1982). Fatty liver is determined by 
chemical analysis of a liver biopsy for triacylglycerol (TAG) or total lipid. Because there is 
no published or generally accepted definition of fatty liver, fatty liver can be defined as the 
percentage of liver triacylglycerol (TAG) that causes detrimental effects to the health status, 
well-being, productivity, or reproductive performance of a cow and is categorized into 
clinical, subclinical, and nonclinical. Clinical fatty liver (> 10% liver TAG on wet weight 
basis) decreases milk production and feed intake by more than 50% and in severe cases 
causes the death of the cow by liver and kidney failure or cardiac arrest. Cows with 
subclinical fatty liver (5-10% liver TAG) produce and eat similarly or even more than cows 
with normal fatty liver (< 5% liver TAG); however, their health status and reproductive 
performance can be affected negatively. Therefore, a treatment for fatty liver would save 
millions of dollars yearly in treatment, replacement, and production losses for U.S. dairy 
farmers (Littledike et al., 1981). 
A previous study in our group demonstrated that continuous, intravenous infusions of 
10 mg/d of glucagon for 14 d decrease concentrations of liver TAG in cows that were 
subjected to a protocol to induce fatty liver (Hippen et al., 1999b). Glucagon is a pancreatic 
hormone that improves the carbohydrate status of cows by stimulating hepatic 
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gluconeogenesis, glycogenolysis, amino acid uptake, and ureagenesis (Donlcin and 
Armentano, 1995; Flakoll et al., 1994). Intravenous infusions of glucagon, however, are not 
practical for on-farm use. 
The overall objccti ve of the current study was to test whether more practical multiple 
subcutaneous injections of glucagon for 14 d causes metabolic responses similar to 
intravenous infusion and, therefore, could be used as a potential treatment of fatty liver. 
More specifically, the objective was to determine the effects of subcutaneous injection of 
2.5 and 5 mg of glucagon every 8 h for 14 d on liver composition, concentrations of key 
constituents in plasma, milk production and composition, health status, and reproductive 
performance in dairy cows during early lactation. 
Dissertation Organization 
This dissertation is presented in the form of three complete papers already submitted for 
publication in the Journal of Dairy Science. These papers have been prepared from research 
performed to partially fulfill the requirements for a Ph.D. degree. Each paper is complete in 
itself and is in the format prescribed by the Journal of Dairy Science, The three papers 
represent different aspects of two related studies. The first paper, entitled "Metabolic 
responses of lactating dairy cows to single and multiple injections of glucagon" describes 
the metabolic responses of lactating dairy cows to subcutaneous injections of 2.5 and 5 mg 
of glucagon during the 8-h post-injection period. The second paper, entitled "Potential 
treatment of fatty liver with 14-day subcutaneous injections of glucagon" describes the 
metabolic responses of lactating dairy cows to subcutaneous injections of 2.5 and 5 mg of 
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glucagon every 8 h during the 14-d injection period. The third paper, entitled "Effects of 
exogenous glucagon and fatty liver on health status and reproductive performance of 
lactating dairy cows" describes the health status and reproductive performance of lactating 
dairy cows as affected by elevated concentrations of liver TAG and subcutaneous injections 
of 2.5 and 5 mg of glucagon every 8 h for 14 d. The three papers are preceded by a 
literature review and are followed by general conclusions consisting of a general discussion 
and recommendations for future research. The dissertation ends with the references for the 
literature review and the general discussion and acknowledgments. 
Literature Review 
Introduction. 
Fatty liver (i.e., hepatic lipidosis) is a major metabolic disease that negatively affects 
the health status, well-being, productivity, and reproductive performance of dairy cows 
(Acorda et al., 1994a, b; Gerloff et al., 1986b; Johannsen et al., 1993; Jorritsma et al., 2001; 
Reid, 1980; Reid and Roberts, 1982). Fatty liver costs U.S. dairy farmers millions of dollars 
each year because of increased veterinary costs, longer calving interval, decreased milk 
production, and decreased average lifetime of cows (Littledike et al., 1981). The pathology 
and etiology of fatty liver and ketosis, a closely associated disease, has been studied for over 
20 yr by our research group to find a possible treatment and/or preventative for fatty liver. 
Glucagon is a pancreatic hormone, with a half-life of 5 min in the blood of cows (de 
Boer et al., 1986), that improves the carbohydrate status of dairy cows by increasing hepatic 
gluconcogenesis, glycogenosis, amino acid uptake, and ureagenesis (Donkin and 
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Armentano, 1995). A previous study by our research group demonstrated that continuous, 
intravenous infusions of glucagon can decrease concentrations of liver TAG and are, 
therefore, a potential preventative and/or treatment for fatty liver (Hippen et al., 1999b). 
The current literature review will describe first what is known about the pathology and 
etiology of fatty liver. Next, the review will summarize some of the current and potential 
treatments for fatty liver and their limitations. Then, the review will shift its focus to 
glucagon and its potential mode of action for prevention and/or treatment of fatty liver, and 
will end with a short summary and concluding remarks. 
Fatty Liver. 
Fatty liver (i.e., hepatic lipidosis) is one of the major metabolic diseases in animals and 
humans (Gruffat et al., 1996). In humans, fatty liver is associated strongly with obesity, non-
insulin dependent diabetes, parenteral nutrition, pregnancy, burns, and excessive alcohol 
consumption (Chitturi and Farrell, 2001 ). In poultry, it is common in laying hens. Lipid-
infiltrated liver of geese that are force-fed with carbohydrates is a culinary delicacy in France. 
In ruminants, it is known as pregnancy toxemia in sheep and fat cow syndrome or fatty liver 
in cows (Gruffat et al., 1996). Fatty liver in dairy cows occurs primarily in the first 4 wk after 
calving (Herdt, 1988), but it can occur also at other times when the energy intake of cows, 
particularly obese cows, is insufficient to meet nutrient requirements (Gerloff et al., 1984; 
Wcntink et al., 1992). 
Epidemiology of Fatty Liver. Fatty liver is categorized primarily by the degree of lipid 
infiltration of the liver into mild, moderate, and severe. Lipid infiltration is measured either 
by chemical or histological analysis of liver samples (Gaal et al., 1983), and the reference 
ranges of the categories and the units of measurement vary between reports (Gerloff et al., 
1986b; Jorritsma et al., 2001; Reid, 1980; Staufenbiel et al., 1990). Over 50% of dairy cows 
have either moderate or severe fatty liver in the early postpartal period (Table 1). 
Table 1. Incidence of fatty liver in dairy cows. 
Country Breed Category of 
Fatty Liver 
Incidence Reference 
England Holstein Moderate 
Severe 
48% 
15% 
Reid, 1980 
England Guernsey Moderate 
Severe 
33% 
5% 
Reid, 1980 
Finland Ayrshire Severe 15% Grôhn et al., 1987 
France n.r.1 Moderate 
Severe 
65% 
5% 
Mazur et al., 1988 
Germany n.r. Moderate 
Severe 
53% 
20% 
Schàfer et al.. 1991 
Germany n.r. Moderate 
Severe 
40% 
22% 
Staufenbiel et al., 1990 
Japan Holstein Moderate 
Severe 
47% 
12% 
Acorda et al., 1994a 
Japan Holstein Moderate 
Severe 
42% 
8% 
Acorda et al., 1994b 
Japan Holstein Moderate 
Severe 
33% 
11% 
Acorda et al., 1995 
Netherlands n.r. Moderate 45% Jorritsma et al., 2000 
Netherlands n.r. Moderate 54% Jorritsma et al., 2001 
USA n.r. Moderate 
Severe 
20% 
15% 
Gerloff et al., 1986b 
USA n.r. Severe 24% Herdt, 1991 
^ n.r. = not reported. 
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Gross Pathology of Fatty Liver. The excessive infiltration of lipids, or more 
specifically of TAG, causes gross and microscopic alterations of the liver that become greater 
with greater infiltration of lipids. The liver is enlarged and swollen and has round edges and 
a pale to yellow appearance (Kapp, 1979; Morrow- et al.. 1979). Adrenal glands, kidney, and 
cardiac and skeletal muscles also are infiltrated with excessive amounts of TAG (Kapp, 1979, 
1989; Morrow et al., 1979; Reid and Roberts, 1982; Saarinen and Shaw, 1950). Other gross 
pathological findings in cows with severe fatty liver are a) myocarditis, b) necrosis in kidney, 
ovarian, muscle, and uterine tissue, c) necrosis and involution of the pituitary gland, d) 
involution of the pancreas and lymphatic system, and e) necrosis, inflammation, and 
ulceration of the gastrointestinal tract (Julien et al.. 1977; Kapp, 1979, 1989; Morrow et al., 
1979; Reid and Roberts, 1982; Saarinen and Shaw, 1950; Shaw. 1956). 
Histological Pathology of Fatty liver. Histological findings in cows with fatty liver 
include a) fatty cysts in liver parenchyma, b) increased cell volume of hepatocytes, c) 
mitochondrial damage, d) compression and decreased volume of nucleus, rough 
endoplasmatic reticulum, sinusoids, and other organelles, and e) decreased number of 
organelles (Johannsen et al.. 1992, 1993; Morrow, 1979; Kapp, 1979, 1989; Reid, 1973; 
Reid and Collins, 1980). Accumulation of TAG in cows with mild fatty liver is limited to 
the centrilobular part near the hepatic vein and extends to the midzonal and then to the 
periportal parts with increased concentrations of liver TAG (Reid and Collins, 1980; 
Veenhuizen et al., 1991). The microscopic alterations affect cellular integrity and function of 
hepatocytes and, therefore, causes necrosis and cellular leakage, which is demonstrated by 
increased concentrations of liver enzymes and bile constituents in plasma (Table 2). 
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Table 2. Effect of fatty liver on concentrations of liver constituents in plasma of lactating 
dairy cows. 
Constituent Effect Reference 
Alkaline phosphatase + Staufenbiel et al., 1992; van den Top et al., 1996; 
Wensing et al., 1997 
Alanine aminotransferase + Johannsen et al., 1988 
Alkaline phosphatase + Staufenbiel et al., 1992; Wensing et al., 1997 
Aspartate aminotransferase ++ Grôhn et al.,1987; Johannsen et al., 1988,1991, 
1992; Nakagawa et al., 1997; Rehage et al., 1996; 
Reid and Collins, 1980; Reid et al., 1983b; Schâfer 
et al., 1991; Wensing et al., 1997 
Bilirubin ++ Johannsen et al., 1988,1991; Rehage et al., 1996; 
Reid and Collins, 1980; Reid et al., 1983b; 
Staufenbiel et al., 1992; West, 1990 
Bile acid ++ Rehage et al., 1999 
Cholic acid ++ Szaniszlô and Karsai, 1991; West, 1990, 1991 
y-Glutamyl transferase ++ Rehage et al., 1996 
Glutamate dehydrogenase +++ Ohtsuka et al., 2001; Rehage et al., 1996; 
Staufenbiel et al., 1990,1992,1993 
Lactate dehydrogenase + van den Top et al., 1996; Wensing et al., 1997 
Malondialdehvde ++ Mudron et al., 1999 
Ornithine carbamoyl + Grôhn et al.,1983; Morrow et al., 1979; Reid and 
transferase Collins, 1980; Reid et al., 1986 
Sorbitol dehydrogenase + Grôhn et al.,1983; Morrow et al., 1979 
«-Tocopherol — Mudron et al., 1997,1999 
1 The symbols + and - mean increase and decrease, respectively, and the number of symbols 
represents slight, moderate, or strong effect. 
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Plasma concentrations of enzymes that have a greater specificity for liver are increased 
the greatest amount. The increase in bile constituents (bilirubin, bile acids, and cholic acid) 
in plasma indicates that bile flow is decreased in cows with fatty liver, and, therefore, bile 
accumulates in the liver, which is supported by the effecti veness of choleretic agents in 
treatment of fatty liver (Furll, 1993; Karatzias et al., 1993). High concentrations of bile are 
toxic and increase the production of free radicals in the liver, which can cause inflammation 
and tissue damage (Ljubuncic et al., 2000). Increased concentrations of free radicals in the 
liver are demonstrated by higher concentrations of malondi aldehyde, one of the endproducts 
of lipid peroxidation, and lower concentrations of «-tocopherol (Mudron et al., 1997, 1999), 
an antioxidant in plasma and to a smaller extent in the liver (Table 3). 
The increase in concentrations of liver TAG is accompanied by decreases in 
concentrations of structural lipids (cholesterol and phospholipids), energy precursors (citrate), 
and energy storage molecules (glycogen). Decreased concentrations of glycogen particularly 
exacerbate the detrimental effects of fatty liver. Therefore, Drackley et al. (1992) 
recommended the use of the ratio of liver TAG to liver glycogen, rather than liver TAG, as a 
diagnostic indicator for fatty liver. Fatty liver is associated also with elevated 
concentrations of NEFA, BHBA, and acetoacetate in blood, all of which can be cytotoxic at 
high concentrations. 
Fatty liver does not affect concentrations of proteins that are important in lipid 
packaging and secretion (apoprotein B and microsomal triglyceride transfer protein) except 
for protein kinase C (Table 3), which is involved in posttranslational modification of 
apoprotein A-l (Yoshino et al., 1993) and carnitine palmitoyltransferase, which is involved 
in P-oxidation and ketogenesis (Mizutani et al.. 1999). Plasma concentration of lipids, 
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lipoproteins (apoproteins A-I, B-100, and C-III), and proteins (lecithin-cholesterol 
transferase) involved in lipid transport, however, are decreased (Table 4), which indicates 
decreased secretion of lipoproteins, specifically of VLDL (Katoh, 2002). 
Table 3. Effect of fatty liver on liver composition in lactating dairy cows. 
Constituent of Liver Effect1 Reference 
Acetoacetate Mills et al., 1986a 
Apoprotein B 0 Gruffat et al., 1997 
BHBA ++ Mills et al., 1986a 
Carnitine 
— 
Mizutani et al., 1999 
palmitoyltransferase 
Cholesterol, total - van den Top et al., 1996 
Cholesterol, free - Brumby et al., 1975; Saarinen and Shaw, 1950 
Cholesteryl ester + Brumby et al., 1975; Saarinen and Shaw, 1950 
Citrate - Mills et al., 1986a 
Glycogen Johannsen et al., 1992; Paulovâ et al., 1990; Rehage et 
al., 1996: Schiller et al., 1991 ; van den Top et al., 1996 
Malondi aldehyde + Mudron et al., 1999 
Microsomal triglyceride 0 Brcmmer et al., 2000 
transfer protein 
NEFA + Brumby et al., 1975 
Phospholipids 
— 
Brumby et al.. 1975; Fronk et al.. 1980; Gruffat et al., 
1997; Herdt et al., 1983; van den Top et al., 1996 
Protein kinase C 
-
Katoh, 1994 
Triacylglycerol +++ Brumby et al., 1975; Gruffat et al., 1997; Herdt et al., 
1983; Mudron et al., 1999; van den Top et al., 1996 
1 The symbols + and - mean increase and decrease, respectively, and the number of symbols 
represents slight, moderate, or strong effect; 0 means no effect. 
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Based on clinical and histological findings, one possible mechanism for decreased 
VLDL secretion could be a) decreased VLDL transport from endoplasmatic reticulum to 
golgi apparatus, b) alteration of glycosylation of apoprotein B-100, c) decreased formation 
of secretory vesicles, and d) decreased migration of secretory vesicles from golgi apparatus 
to cell membrane (Gruffat et al., 1996). 
Fatty liver also might interfere with the function of apoproteins. The major lipoprotein 
in VLDL is apoprotein B-100, whereas apoprotein A-l and C-III are primarily associated 
with HDL-particles. Apoprotein A-I activates lecithin-cholesterol acyltransfera.se, which 
esterifies free cholesterol with phosphatidylcholine to cholesteryl esters and 
lysophosphatidylcholine in HDL particles (Nakagawa et al., 1997; Nakagawa-Ueta and 
Katoh, 2000, 2002). Decreased concentrations of apoprotein A-I and lecithin-cholesterol 
acyltransferase in cows with fatty liver decreases the synthesis of cholesteryl esters, which 
are important precursors for the synthesis of steroids. 
Metabolic Pathology of Fatty Liver. Histological and compositional changes in fatty 
liver affect carbohydrate, lipid, and protein metabolism in hepatocytes (Table 5). Increased 
lipid infiltration of the liver decreases production of energy precursors in the liver 
(decreased giuconeogenesis and variable effects on ketogenesis and (3-oxidation) and 
increases lipogenesis in the liver. Furthermore, ureagenesis and the ability of insulin to 
increase protein synthesis is decreased (Strang et al., 1998b), which explains the elevated 
concentrations of plasma ammonia in cows with fatty liver (Rehage et al., 2001). 
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Table 4. Effect of fatty liver on concentrations of compounds involved in lipid transport 
in plasma of lactating dairy cows. 
Constituent Effect1 Reference 
Apoprotein A-l 
Apoprotein B-100 
Apoprotein C-III 
Cholesterol, total 
Cholesterol, free 
Cholesteryl ester 
VLDL-cholestcrol 
LDL-cholesterol 
HDL-cholesterol 
Lecithin cholesterol 
acyltransferase 
Phospholipids 
VLDL-phospholipids 
LDL-phospholipids 
HDL-phospholipids 
Triacylglycerol 
VLDL-triacyglycerol 
LDL-triacyglycerol 
HDL-tri acyl gl ycerol 
V1JDL-protein 
LDL-protein 
HDL-protein 
Bobowiec et al., 1997: Marcos et al., 1990; Mazur et al., 
1989; Nakagawa et al., 1997; Oikawa et al., 1997 
Cai dot et al., 1988; Itoh et al., 1997; Marcos et al., 1990; 
Nakagawa et al., 1997; Oikawa et al., 1997 
Bobowiec et al., 1997; Yamamoto et al., 2001 
Gerloff et al., 1986b; Herdt et al., 1983; Holtenius, 1989; 
Holtenius and Hjort, 1990; Rehage et al., 1996; Reid et 
al., 1983b 
Mazur et al., 1989; Nakagawa et al., 1997; Yamamoto et 
al., 2001; Yamdagni and Schultz, 1970 
Brumby et al., 1975; Mazur et al., 1989; Yamamoto et al., 
2001; Yamdagni and Schultz, 1970 
Bobowiec et al., 1997; Holtenius and Hjort, 1990; 
Rayssiguier et al., 1988 
Bobowiec et al., 1997; Holtenius and Hjort, 1990; Mazur 
et al., 1989; Rayssiguier et al., 1988 
Bobowiec et al., 1997; Holtenius and Hjort, 1990; Mazur 
et al., 1989; Rayssiguier et al., 1988 
Nakagawa et al., 1997; Nakagawa-Ueta and Katoh, 2000; 
Uchida et al., 1995 
Brumby et al., 1975; Herdt et al., 1983; Holtenius, 1989: 
Holtenius and Hjort, 1990; Nakagawa et al., 1997; 
Yamamoto et al., 2001; Yamdagni and Schultz, 1970 
Bobowiec et al., 1997; Rayssiguier et al., 1988 
Bobowiec et al., 1997; Mazur et al., 1989; Rayssiguier et 
al., 1988 
Bobowiec et al., 1997; Mazur et al., 1989; Rayssiguier et 
al., 1988 
Fronk et al., 1980; Herdt et al., 1983; Holtenius and Hjort, 
1990; Mazur et al., 1989; Nakagawa et al., 1997; 
Yamdagni and Schultz, 1970 
Bobowiec et al., 1997; Grummer et al., 1990; Holtenius 
and Hjort, 1990; Rayssiguier et al., 1988 
Bobowiec et al., 1997; Holtenius and Hjort, 1990; Mazur 
et al., 1989; Rayssiguier et al., 1988 
Bobowiec et al., 1997; Holtenius and Hjort, 1990; 
Rayssiguier et al., 1988 
Bobowiec et al., 1997; 
Bobowiec et al., 1997; Mazur et al., 1989 
Bobowiec et al., 1997; Mazur et al., 1989 
1 The symbols + and - mean increase and decrease, respectively, and the number of symbols 
represents slight, moderate, or strong effect: 0 means no effect. 
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Table 5. Effect of fatty liver on metabolic function in bovine hepatocytes and adipocytes. 
Pathway Effect Reference 
Hepatocytes: 
Gluconeogenesis Mills et al.. 1986b; Cardôrniga-Valino et al., 1997; 
Rukkwamsuk et al., 1999a; Veenhuizen et al., 1991 
Insulin clearance - Strang et al., 1998b 
Ketogenesis ± Drackley et al., 1992; Mills et al., 1986b 
Lipogenesis +++ Cadôrniga-Valino et al., 1997; Grum et al., 1996 
(3-Oxidation ± Cadôrniga-Valino et al., 1997; Drackley et al., 1992; Grum 
et al., 1996; Mills et al., 1986b 
Ureagenesis 
-
Strang et al., 1998a 
Adipocytes: 
Lipogenesis 0 Rukkwamsuk et al., 1999c 
Iipolysis +++ Rukkwamsuk et al., 1998; Gieseke et al., 1987 
1 The symbols +, -, and ± mean increase, decrease, and variable effect, respectively, and the 
number of symbols represents slight, moderate, or strong effect; 0 means no effect. 
Fatty liver alters the hormonal sensitivity of adipose tissue and the pancreas. 
Lipogenesis is promoted less by insulin and glucose (Rukkwamsuk et al., 1999c), and 
iipolysis is promoted more by adrenaline (Gieseke et al., 1987) and inhibited less by glucose 
and BHBA (Rukkwamsuk et al., 1998). The clearance rates of insulin and other compounds 
in hepatocytes (Herdt, 1988a; Strang et al., 1998b; West, 1990), and probably in other 
organs, and the uptake of glucose by peripheral tissues is decreased (Holtenius and Trâvén, 
1990; Steen et al., 1997). 
Fatty liver affects not only the hormonal sensitivity of tissues but also alters the 
concentration of hormones themselves. Synthesis and/or secretion of insulin growth factor-
1 by liver, glucocorticoids by the adrenal glands, glucagon and insulin by the pancreas, and 
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thyroxin and triiodothyronine by the thyroid glands arc decreased (Table 6). Additionally, 
secretion of insulin by the pancreas is promoted less by glucose and glucagon (Holtenius 
and Trâvén, 1990; Hove et al., 1978; Steen et al., 1997). Concentrations of insulin are 
increased in rare cases when insulin clearance is strongly decreased (Strang et al., 1998b) 
and cows have type II diabetes (Holtenius and Holtenius, 1996; Mostaghni and Ivoghli, 
1977). 
Table 6. Effect of fatty liver on plasma concentrations of hormones in lactating dairy cows. 
Constituent Effect1 Reference 
Glucagon - de Boer et al., 1985, 1986 
Glucocorticoids - Morrow et al., 1979 
Growth hormone + de Boer et al., 1986 
Insulin-like growth factor-1 — Formigoni et al., 1996 
Insulin ± De Boer et al., 1985,1986; Gerloff et al., 1986b; 
Holtenius and Holtenius, 1996; Reid et al., 1983a 
Thyroxine 
-
Gerloff et al., 1986a; Kapp et al., 1979 
T riiodothyronine 
-
Gerloff et al., 1986a 
1 The symbols +, -, and ± mean increase, decrease and variable effect, respectively, and the 
number of symbols represents slight, moderate, or strong effect. 
Clinical Pathology of Fatty Liver. The hormonal and pathological changes associated 
with fatty liver affect concentrations of metabolites and minerals in plasma (Table 7). 
Metabolites can be used either as energy sources or as precursors. Decreased concentrations 
of metabolites such as a-amino N, branched-chain amino acids, and glucose can decrease the 
function of organs. 
Table 7. Effect of fatty liver on concentrations of plasma metabolites and minerals in 
lactating dairy cows. 
Constituent Effect1 Reference 
Acctoacetate +++ de Boer et al., 1985; Grôhn et al..1983, 1987; Johannsen et al., 
1992; Mills et al.. 1986a; Staufenbiel et al., 1992 
Albumin — Nakagawa et al., 1997; Reid and Collins, 1980; Reid et al., 
1979a, b, 1983a, b; West, 1990 
a-Amino N - de Boer et al., 1985 
Ammonia + Rehage et al., 1999, 2001; Zhu et al., 2000 
BHBA +++ de Boer et al., 1985; Johannsen et al., 1988; Mazur et al., 1988; 
Ohtsuka et al., 2001; Rehage et al., 1996; Schafer et al., 1991 
Branched-chain - Rehage et al., 1999, 2001 
amino acids 
Copper + Reid et al., 1986 
Glucose ± de Boer et al., 1985, 1986; Grôhn et al.,1983; Mazur et al., 
1988; Ohtsuka et al., 2001; Reid et al., 1979a, 1983a, b; 
Staufenbiel et al., 1992; West, 1990 
Iron - Reid et al., 1986 
Magnesium - Reid et al., 1983a, b, 1986 
NEFA +++ de Boer et al., 1986; Fronk et al., 1980; Gerloff et al., 1986b; 
Holtenius and Hjort, 1990; Mazur et al., 1988, 1989; 
Nakagawa et al., 1997; Rehage et al., 1996; Reid et al., 1979a, 
1983a, b 
Protein - Staufenbiel et al., 1992 
Urea N - West, 1990 
The symbols + and - mean increase and decrease, respectively, and the number of symbols 
represents slight, moderate, or strong effect. 
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Elevated concentrations of ammonia, NEFA, BHBA, and acetoacetate can decrease the 
function of organs because of their toxicity at high concentrations and because of their 
metabolic effects. Elevated concentrations of NEFA increase lipogenesis and ketogenesis in 
hepatocytes and decrease insulin secretion by the pancreas (Cadôrniga-Valino et al., 1997; 
Zhou and Grill, 1995). High concentrations of BHBA and acetoacetate decrease [3-
oxidation, gluconeogenesis, and the citric acid cycle in hepatocytes and decrease insulin 
secretion by the pancreas in the absence of glucose (Atwal and Sauer, 1973; Drackley et al., 
1991; Mal ai s se et al., 1990; Zhou and Grill, 1995). 
The histological, metabolic, and hormonal changes associated with fatty liver negatively 
affect milk production, health status, and reproductive performance of dairy cows (Tables 8 
and 9). The negative effects of fatty liver persist months after liver TAG decreased back to 
their baseline concentration because fat infiltration in cows is short-term and reversible 
(Chitturi and Farrell, 2001), whereas its detrimental effects on other tissues are long-term and 
sometimes irreversible. 
Because the negative effects on health status, reproduction performance, and milk 
production are more detrimental at higher concentrations of liver triacylglycerol (Breukink 
and Wensing, 1997; Herdt, 1991; Veenhuizen et al., 1991), another system for categorization 
of fatty liver is based on its effects and cows are categorized into clinical, subclinical, and no 
fatty liver. Clinical fatty liver, which is also called hepatic encephalopathy, fat cow or fat cow 
mobilization syndrome, is defined by anorexia, strongly decreased milk production 
(Veenhuizen et al., 1991), depressed consciousness, ataxia, somnolency, coma, and elevated 
liver enzymes in plasma (Mudron et al., 1999; Rehage et al., 1999), and also can include 
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fever, ketonuria, and decreased glucocorticoid concentrations (Morrow et al., 1979). The 
recovery rate is less than 75%, because some cows with clinical fatty liver remain anorexic 
despite intensive treatment (Gerloff et al., 1986b; Morrow et al.. 1979; Mudron et al., 1999). 
Cows with subclinical fatty liver have elevated concentrations of liver TAG and a 
compromised health status and reproductive performance (Tables 8 and 9), but their behavior, 
appetite, and milk production may not be different from no fatty liver or normal cows. Cows 
with subclinical fatty liver often have higher milk production than normal cows (Gerloff et al.. 
1986b; Staufenbiel et al., 1993). 
Immunological Pathology of Fatty Liver. The incidence of fatty li ver is strongly 
associated with the incidence of other metabolic diseases (ketosis, displaced abomasum, and 
milk fever) because all metabolic diseases have in common that the cows either are or will be 
in a strong negative energy balance. The association of fatty liver with infectious diseases is 
caused a) by the involvement of liver in the response of the body to infection, b) by the 
inflammatory effect of fatty liver, c) by compromising the nutritional status of the animal, and 
d) by increasing/decreasing concentrations of compounds that negatively/positively affect the 
immune response. 
Cows with fatty liver have decreased concentrations of leukocytes, lymphocytes, 
eosinophils, monocytes, and mature neutrophils (Morrow et al., 1979; Reid et al., 1984, 1986; 
Wensing et al., 1997). Furthermore, the function of polymorphonuclear neutrophilic 
granulocytes (Zerbe et al., 2000) arc altered, the lymphocyte histogenesis and interferon 
production in leukocytes is decreased (Szuster-Ciesielska et al., 1995; Zhou et al., 1997), and 
the clearance of endotoxins is decreased (Andersen, 1988; Jarlov et al., 1983). 
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Table 8. Effect of fatty liver on health status in dairy cows. 
Disorder Effect' Reference 
Displaced abomasum +++ Holtenius and Niskanen, 1985; Muylle et al., 1990; Rehage 
et al., 1996; Wada et al., 1995; Wensing et al., 1997 
Fever + Morrow et al., 1979 
Ketosis +++ Grôhn et al.,1987; Morrow et al., 1979; Veenhuizen et ai., 
1991 
Laminitis + Fronk et al., 1980; Rehage et al., 1996 
Mastitis 44- Morrow et al.. 1979 
Metritis ++ Haraszti et al., 1982a; Heinonen et al., 1987 
Milk fever + Grôhn et al.,1987; Higgins and Anderson, 1983; Morrow et 
al., 1979 
Retained placenta + Haraszti et al., 1982a; Heinonen et al., 1987; Morrow et al., 
1979 
1 The number of + represents slight, moderate, or strong association with fatty liver. 
The decreased immune response is demonstrated further by decreased lymphoid 
infiltration of skin allotransplants (Wentink et al., 1999) and smaller and delayed specific 
immunoreactivity against tetanus toxoid (Wentink et al., 1997). The decreased and delayed 
immune responses in cows with fatty liver increase the length and severity of mastitis (Hill et 
al., 1985; Kremer et al., 1993) and increase the incidence of metritis (Haraszti et al., 1982a; 
Heinonen et al., 1987). The incidence and severity of infectious diseases is increased 
somewhat in the peripartal period, even without the presence of fatty liver, because the 
immune function is suppressed (Lee et al., 1998; Moreira da Silva et al., 1998; Zerbe et al., 
1998) and concentrations of the proinflammatory cytokine, tumor necrosis factor-alpha 
(TNFa), are increased (Sordillo et al., 1995). 
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Cows with fatty liver have an inflammatory response that is indicated by increased 
concentrations of haptoglobin and serum amyloid A, acute phase proteins (Katoh et al., 2001, 
2002; Nakagawa et al., 1997; Yamamoto et al., 2000; Yoshino et al., 1993), that are induced 
by increased concentrations of TNFoc (Ohtsuka et al., 2001). Increased concentrations of 
TNFa have been shown to decrease albumin synthesis in the liver (Zupke et al., 1998). 
Haptoglobin binds to apoprotein A-I (Kunitake et al., 1994), which might interfere with the 
functions of apoprotein A-I in HDL receptor binding and in the exchange of cholesteryl 
esters in steroidogenic tissues (Bauchart, 1993; Hoiian et al., 1991). 
Fatty liver is associated with limited nutrient availability to the immune system, which 
decreases the immune function (Filar et al., 1992). Fatty liver increases concentrations of 
BHBA, NEFA, and acetoacetatc, which at high concentrations inhibit the immune function 
(Franklin et al., 1991; Kandefer-Szerszen et al., 1992; Klucinski et al.. 1988a, b; Lacetera et 
al., 2002; Sartorelli et al., 2000; Stephen et al., 1990; Suriyasathaporn et al. 1999). Fatty liver 
decreases concentrations of insulin growth factor-1, which stimulates neutrophil function 
(Zhao et al., 1993). 
Reproductive Pathology and Fatty Liver. Fatty liver decreases reproductive 
performance by delaying uterine involution (Higgins and Anderson, 1983). Delayed uterine 
involution is caused partly by an increased incidence, length, and severity of endometritis in 
cows with fatty liver (Haraszti et al., 1982a; Markusfeld, 1987; Sheldon et al., 2002), which is 
caused by the delayed and decreased immune response in the uterus (Zerbe et al.. 2000). 
Delayed initiation of ovarian activity (Table 9) can be explained partly by the decreased and 
delayed synthesis of steroidogenic hormones, i. e.. progesterone and luteinizing hormone 
(Reid, 1984; Ropstad et al., 1989; Zhou et al., 1997). Another reason for the delay is the 
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strong negative energy balance (Kruip et al., 1996; Rukkwamsuk et al., 1999b; Wensing et al., 
1997), which decreases the availability of precursors for follicular development. Additionally, 
decreased concentrations of insulin growth factor-1 and insulin impair normal ovarian 
function (Gong et al., 2002; Lucy et al.. 1992; Miyoshi et al., 2001), and high concentrations 
of NEFA (Comin et al., 2002) also can impair normal ovarian function. 
Table 9. Effect of fatty liver on reproductive performance in dairy cows. 
Parameter Effect' Reference 
First ovarian activity ++ Markusfeld, 1987; Reid et al., 1983b Rukkwamsuk et 
al., 1999b 
First ovulation + Reid et al., 1983b 
First estrus + Jorritsma et al., 2000; Paulovâ et al., 1990; Reid et al., 
1983b 
First insemination + Reid et al., 1983b 
Days open ++ Heinonen et al., 1987; Paulovâ et al., 1990; Reid, 1983, 
1984; Reid et al., 1979a, b, 1983b; Schafer et al., 1988 
Pregnancy rate ++ Haraszti et al., 1982a, b; Jorritsma et al., 2000 
Services/cow + Paulovâ et al., 1990; Reid, 1983; Reid et al., 1979a, h; 
Schâfer et al., 1988 
1 The number of + represents slight, moderate, or strong association with fatty liver. 
The decreased pregnancy rate in cows with fatty liver (Table 9) can be explained by the 
decreased number of oocytes that survive during early embryonic development (Kruip et al., 
1996; Wensing et al., 1997). The decreased embryo survival persists until 120 days 
postpartum, which indicates that follicular development starts in the early postpartal period 
(Asian et al., 2002; Gong et al., 2002) and that fatty liver in the early postpartal period 
decreases embryo survival until after 120 days postpartum. 
Etiology of Fatty Liver. Fatty liver develops when the hepatic uptake of NEFA 
exceeds the capability of the liver to oxidize and secrete lipids. This imbalance occurs 
primarily in early lactation, but it can occur also in late pregnancy when cows arc starved or 
pregnant with more than one fetus (Gerloff et al., 1984; Wentink et al., 1992). Risk factors 
for fatty liver can be grouped into four categories: nutritional, management, pathogenic, and 
genetics. 
The nutritional risk factors are related to either increased lipolysis of adipose tissue, 
which increases NEFA uptake of the liver, or to nutrients or toxins that affect hepatic 
lipogenesis, (3-oxidation of fatty acids, ketogenesis, and/or lipid packaging and secretion 
(Koteish and Diehl, 2001). Increased lipolysis of adipose is promoted by obesity, because 
obese animals have a stronger decreased feed intake and, therefore, a stronger negative 
energy balance during metabolically and immunologically challenging situations such as the 
peripartal period. Berries et al. (1992) demonstrated that lipid infiltration of the liver can be 
decreased by increasing feed intake around parturition. Reasons for the greater negative 
energy balance are that adipose tissue down-regulates feed intake and secretes hormone-like 
compounds such as leptin and the proinflammatory cytokine, TNFcx, which down-regulate 
feed intake and increase catabolism and inflammation (MacDougald and Mandrup, 2002; 
Prins and O'Rahilly, 1997 ; Tray h urn and Beattie, 2001). 
Unbalanced diets that are either high in energy or protein (Julien et al., 1977; Holtenius 
and Hjort, 1990) and high-concentrate diets of fat or to a smaller extent corn (Vazquez-Anon 
et al., 1997) increase the risk for fatty liver in comparison to balanced and lower concentrate 
diets (Table 10). The negative effects of high-concentrate diets suggest that ruminai acidosis 
is important in the etiology of fatty liver. Obesity does not necessarily cause fatty liver. 
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however, especially when cows stay healthy, have low milk production, and/or have a high 
feed intake (Neil son et al., 1983; Smith et al., 1997; Van de Haar et al., 1999). Preliminary 
research in our group indicates that cows that were obese as heifers are more prone to 
develop fatty liver after calving, which suggests nutritional imprinting of pancreatic, 
hepatic, and/or neural genes (Levin, 2000; Nilsson et al., 1998; Waterland and Garza, 2002). 
Table 10. Nutritional risk factors for fatty liver in lactating dairy cows. 
Risk factor Effect' Reference 
Overfeeding prepartum: 
Extra corn + Fronk et al., 1980; Holtenius and Hjort, 1990 
Extra energy and protein + Jonsson and Pehrson, 1983; Schafer et al., 1988 
Extra fat + Skaar et al., 1989; Vazquez-Anon et al., 1997 
Extra protein ++ Julien et al., 1977 
High concentrate + Grum et al., 1996; Holtenius et al., 1993, 1996 
Restriction of feed intake: 
Fasting + Brumby et al., 1975; Furl! et al., 1993; Iiove et al., 
1978; Reid, 1973; Saarinen and Shaw, 1950 
Feed restriction + Bahaa et al., 1997; de Boer et al., 1985, 1986; 
Johannsen et al,, 1992; Staufenbiel et al., 1992 
Feed restriction and + Drackley et al., 1992; Hippen et al., 1999b; Mills et 
1. 3-butanediol al., 1986a 
1 The number of + represents slight, moderate, and strong risk factors for fatty liver. 
Fatty liver can be caused by specific nutrients and toxins that alter lipid metabolism in 
the liver. As an example, dietary methionine is an important precursor for the 
transulfuration pathway, because methionine derivatives inhibit methylation of DNA (Peace 
et al., 1992). Administration of ethionine, a transition state analog of methionine, induces 
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fatty liver by inhibition of protein synthesis in cows (Katoh, 1994). Feed restriction 
combined with estrogen injections induce fatty liver in cows (Grummer et al., 1990; Katoh 
et al.. 1993). The reason is that feed restriction increases lipolysis in adipose tissue and that 
estrogen increases hepatic lipogenesis (Hermier et al., 1994), decreases hepatic (3-oxidation 
(Grimbert et al., 1995), and increases concentrations of endotoxins and proinflammatory 
cytokines (Higuchi et al., 1994; Yin et al., 2000b). Preliminary research in our group 
showed that postpartal diets that contain high concentrations of proteins might increase the 
risk for fatty liver, because they increase the negative energy balance and increase 
concentrations of the ammonia, which is at high concentrations toxic. 
Deficiencies of vitamins and amino acids, particularly of methionine, carnitine 
(Tomomura et al., 1997), choline (Grattagliano et al., 2000), folate (Akesson et al., 1982), 
and niacin (Fukuwatari et al., 2002), have been shown to induce fatty liver in non-
ruminants. Bacteria in the rumen usually supply cows with sufficient vitamins, essential 
amino acids, and antioxidants, but deficiencies can occur during feed changes, spoiled feed, 
and/or higher requirements as in the peripartal period (Mudron et al., 1999). Other nutrients 
that can affect lipid metabolism are sucrose, fructose, lipids, and ethunol, which all have 
been shown to increase lipogenesis. Toxins, such as etomoxir an inhibitor of carnitine 
palmitoyltransferase (Thupari et al., 2002), cause fatty liver by decreasing (3-oxidation 
(Koteish and Diehl, 2001). 
Management factors that are related to nutrition and health status also can influence the 
occurrence of fatty liver. Poor quality feed such as silage high in butyrate increase the 
incidence of fatty liver by increasing BHBA production and decreasing feed intake. 
Therefore, 1, 3-butanediol has been used together with feed restriction to induce an 
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experimental fatty liver (Drackley et al., 1992; Hippen et al., 1999b; Mills et al., 1986a). 
Abrupt feed changes or high-concentrate feeding can cause rumen acidosis, which also is 
associated with fatty liver (Nikov et al., 1981) because the acidosis increases ketogenesis and 
concentrations of endotoxins and pro-inflammatory cytokines (Andersen et al., 1994; Bertoni 
et al., 1997; Furll, 2002; Kushibiki et al., 2002). 
The risk for fatty liver increases with advancing age of cows (Drackley et al., 1992; 
Herdt, 1988; Reid, 1980), which might be related to their higher body condition at calving 
(Gillund et al., 2002; Jorritsma et al., 2000), their higher milk production, their weaker 
immune response, and/or their lower antioxidant status, all of which are independent risk 
factors for fatty liver. Other risk factors for fatty liver are inadequate space for 
periparturient cows, poor sanitary conditions, and/or poor air circulation, which causes 
stress (Luthman and Holtenius, 1972) and increases the risk for infections during the 
peri parlai period when cows are more susceptible to infections (Furll, 2002). Diseases, 
particularly displaced abomasum, locomotive disorders, toxic mastitis, metritis, milk fever, 
and retained placenta, increase lipid infiltration of the liver, because those diseases decrease 
feed intake, increase nutrient requirements, and cause an inflammatory response that 
increases lipolysis in adipose tissue. The strength of the association of a disease with fatty 
liver is related strongly to the degree of negative energy balance the disease causes. 
Genetic factors that increase the risk of fatty liver can include mutations that affect feed 
intake, lipid metabolism in adipose tissue, and lipid metabolism and secretion in liver. More 
specifically, mutations that increase lipogenesis in liver and lipolysis in adipose tissue and 
decrease (3-oxidation and lipid packaging and secretion in the liver are very likely to cause 
fatty liver (Koteish and Diehl, 2001). In comparison to other species, ruminants have lower 
hepatic secretion of VLDL and lower activity of lecithin cholesterol acyltransferase (Graulet 
et al.. 1998; Ha and Barter, 1982). So far. no specific gene has been found in Bovine that 
increases the incidence of fatty liver in the general population. 
In our limited data set of 70 cows, we estimated a heritability of close to zero for 
concentrations of liver TAG. However, for ketosis and displaced abomasum, which both 
are associated closely with fatty liver, herilabilities of 0.18 (Klug and Franz, 1991) and 0.24 
(Geishauser et al., 1996) have been estimated, respectively, which indicate that there might 
be some genetic basis for fatty liver. One problem with genetic selection against fatty liver 
is that high-producing cows generally have mild fatty liver, because a strong negative 
energy balance and insulin resistance at the beginning of lactation enables high milk 
production throughout the lactation (Kruip et al., 1996). 
Treatment and Prevention of Fatty Liver. Because fatty liver is a multi-factorial 
disorder, treatment and prevention of fatty liver varies (Tables 11 and 12). Treatments and 
preventions can be categorized into six groups: 1) oral glucose precursors, 2) hormones, 3) 
rumen fermentation modifiers, 4) choleretic compounds, 5) antioxidants, and 6) vitamins 
and amino acids. 
Clinical fatty liver usually is treated by intravenous infusions of glucose or dextrose 
combined with injections of glucocorticoids for several days and oral administration of a 
glucose precursor in the recovery period (Mudron et al., 1999). The combined treatments 
increase gluconeogenesis and provide energy precursors as fuel for the cow. 
Glucocorticoids differ in the speed and duration of their effectiveness. Non-esterified 
glucocorticoids cause a faster but shorter response than do esterified glucocorticoids. 
Therefore, a combination of different glucocorticoids is recommended for treatment (Stock! 
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et al., 1969). Adrenocorticotropic hormone (ACTH) can substitute for glucocorticoids when 
the adrenal gland functions (Shaw, 1956). Usually, ACTH will replace glucocorticoids in 
prolonged treatment (Fox, 1971). Glucocorticoids can be replaced by insulin, which 
changes the action of the treatment from a more gluconeogenic and immuno-suppressing 
effect to an effect that promotes glucose uptake. 
Separate administration of glucose and hormones is less effective (Hayirli et al., 2002; 
Sakai et al., 1993; Shpigel et al., 1996) because glucose inhibits rather than increases 
gluconeogenesis, and therefore, has a short-term effect. The effectiveness of hormones also 
depends on the availability of precursors. Other combinations of hormones and 
carbohydrates, carbohydrate precursors, and glucose-sparing substances have not been 
tested. For instance, substitution of xylitol for glucose might improve therapeutic effects 
against fatty liver, because xylitol causes stronger increases in insulin concentration and a 
more anti-ketogenic effect (Sakai et al., 1996; Hamada et al., 1982). Invert sugar, a 
combination of glucose and fructose, might improve the effectiveness of treatment, because 
invert sugar inhibits gluconeogenesis less than glucose (Kouider et al., 1978). 
The effectiveness of energy precursors depends on the mode of application (intravenous 
or oral) and on the substrate used. Intravenous application is faster and more efficient, but is 
not applicable for substrates such as glycerol and 1, 2-propanediol (i.e., propylene glycol) 
because they are neurotoxic at high concentrations (Johnson, 1954). Dextrose, glucose, 
fructose, glucose/fructose mixtures, and xylitol are infused intravenously rather than being 
administered orally because rumen bacteria will metabolize most of them without a 
significant increase in concentrations of plasma carbohydrates (Shaw, 1956). 
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Table 11. Treatments for fatty liver/ketosis in lactating dairy cows. 
Treatment Effect1 Reference 
Na-acetate ± Fox, 1971; Shaw, 1956 
ACTH + Fox, 1971; Shaw, 1956 
Chloral hydrate + Fox. 1971; Shaw, 1956 
Na- and K-chl orate + Fox, 1971: Shaw, 1956 
Dchydrocholic acid + Furll, 1993 
Fructose + Kauppinen and Grôhn, 1984 
Glucagon + Hippen et al., 1999b 
Glucocorticoids + Furll et al., 1993; Higgins and Anderson. 1983; Shpigel et 
al., 1996; Stôckl et al.. 1969;Wierda et al., 1987 
Glucose + de Boer et al., 1985; Metzner et al., 1993; Sakai et al., 
1993,1996 
Glucose + fructose ++ Kouider et al., 1978; Kauppinen and Grôhn, 1984 
Glucose + +++ Kauppinen and Grôhn, 1984; Mudron et al., 1999; Shpigel 
glucocorticoids et al., 1996 
Glucose + insulin ++ Sakai et al., 1993 
Glycerol + Pehrson, 1972; Johnson, 1954; Goff et al., 2001a, b 
Insulin ± Fox, 1971; Hayirli et al., 2002 
Ca-lactate + Fox, 1971; S haw, 1956 
Na-lactate + Fox, 1971; Shaw, 1956 
1, 2-Propanediol + Hamada et al., 1982; Kauppinen and Grôhn, 1984 
Mg-propionate + Hamada et al., 1982 
Na-propionate + Pehrson, 1972a, c; Kauppinen and Grôhn. 1984; Schultz, 
1952 
Thiopronine + Tanemura et al., 1985 
Tripropionine + Johnson, 1954 
Xylitol ++ Hamada et al., 1982; Sakai et al., 1996 
The number of + indicates slight, moderate, or strong effectivity as treatment for fatty liver: 
± represents variable effect. 
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Xylitol and glucose/fructose mixtures are superior over dextrose, glucose, and fructose, 
because xylitol is a stronger promoter of insulin secretion and the glucose/fructose mixture 
is less of an inhibitor of gluconeogenesis (Sakai et al., 1996; Kouider et al., 1978). 
Advantages of glucose over fructose are that glucose infusions increase concentrations of 
glucose and insulin more. Disadvantages of glucose infusions are that they decrease feed 
intake and cause hypoglycemia at the end of the treatment period and that considerable 
amounts of glucose are lost via urine (Kouider et al., 1978). Therefore, a glucose/fructose 
mixture has a more beneficial effect than glucose and fructose alone. 
The orally administered substances can be categorized into salts of compounds of 
rumen fluid, which are ammonium lactate, calcium lactate, magnesium propionate, sodium 
acetate, sodium lactate, and sodium propionate, and glucose precursors that are not part of 
rumen fluids (Table 11). The lactate and propionate forms are more beneficial than the 
acetate forms because they are direct glucose precursors. Lactic and propionic acids differ, 
however, in their pathways as precursors. Lactic acid enters gluconeogenesis through 
pyruvate, whereas propionate enters via succinyl-CoA. Propionic acid is used more often. 
Problems with all rumen acids are that they affect the pH of the rumen and potentially of 
blood and that they affect the rumen epithelium. Of the counter-ions, magnesium and 
calcium are more palatable and have less detrimental effects on the pH of the rumen and on 
the concentrations of electrolytes in blood (Schultz, 1952), however, they are less soluble. It 
has been noted that oral administration of sodium propionate and high dosages of ruminai 
acids can cause diarrhea (Kouider et al., 1978; Shaw, 1956). Therefore, moderate dosages 
of a combination of substances with different counter-ions should be most favorable. 
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Oral glucose precursors that are not rumen acids include 1, 2-propanediol, glycerol, and 
tripropionin, the glycerol ester of propionic acid (Table 11). In comparison to the rumen 
acids, specifically sodium propionate, 1, 2-propanediol and glycerol cause less increase in 
plasma glucose and insulin and a larger decrease in volatile fatty acids in the rumen 
(Hamada et al., 1982: Pehrson, 1972a; Schâfer et al., 1975). Another disadvantage is that 
large doses of 1, 2-propanediol and glycerol are neurotoxic. Propylene glycol enters 
gluconeogenic pathway through lactate (Studer et al., 1993), whereas glycerol enters 
through dihydroxyacetone phosphate. In contrast to 1, 2-propanediol, some glycerol is 
converted to propionate in the rumen. Glycerol increases concentrations of glucose slower 
but more persistently than does 1, 2-propanediol (Pehrson, 1972a) and is less neurotoxic and 
more palatable (Johnson, 1954). Tripropionin is used rarely because it is expensive, 
unpalatable, and immiscible in water (Johnson, 1954). Branched-chain amino acids 
detoxify ammonia into glutamine in skeletal muscle and increase concentrations of plasma 
glucagon (Steward et al., 1988), which both can improve survival of rats with fatty liver 
(Kajiwara et al., 1998). Branched-chain amino acids are decreased strongly in fatty liver 
and the decreased ratio of branched-chain to aromatic amino acids might contribute to 
hepatic encephalopathy (Rehage et al., 2001). 
Hormones that are used for prevention and treatment of fatty liver include ACTH, 
glucagon, glucocorticoids, and insulin (Tables 11 and 12). Glucocorticoids and insulin in 
combination with glucose arc the primary hormones that are used to treat fatty liver. The 
advantage of insulin in comparison to glucocorticoids and glucagon is that insulin increases 
glucose uptake in peripheral tissue and somewhat inhibits lipolysis (Table 13). The 
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disadvantage is that it decreases gluconeogenesis and lipogenesis in hepatocytes. Therefore, 
insulin has to be combined with glucose to have a beneficial effect. 
Table 12. Preventatives for fatty liver/ketosis in lactating dairy cows. 
Preventative Effect' Reference 
Choline + Juslin, 1965; Piepenbrink and Overton, 2000 
Clanobutin ++ Karatzias et al., 1993 
Cobalt + Fox, 1971 
Cyanocobalamin + Fox,1971 
CysteamineHCl + Fox,1971 
Growth hormone 0 Fetrow et al., 1999; Maisey et al., 1993 
Insulin 0 Hayirli et al., 2002 
Lysine + Bauchart et al., 1998 
Methionine + McCarthy et al., 1968; Bauchart et al., 1998 
Monensin ++ Duffield et al., 1998; Green et al., 1999; Sauer et al., 1989; 
Stephenson et al., 1997 
Niacin + Dufva et al., 1983 
1, 2-Propanediol ++ Christenscn et al., 1997; Emery et al., 1964; Formigoni et al., 
1996; Grummer et al., 1994; Miettinen et al., 1993; 
Miettinen, 1995; Studer cl a., 1993 
Retinoic acid + Fox,1971 
Thiamine + Fox,1971 
«-Tocopherol + Fox, 1971 
1 The number of + indicates slight, moderate, or strong effectivity as preventative of fatty 
liver; 0 indicates no beneficial effect. 
Glucocorticoids, glucagon, and growth hormone (EST) are very similar in their 
metabolic effects as they relate to fatty liver; glucagon, however, is less lipolytic and more 
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glycogenolytic, gluconeogenic, and insulinotropic than are glucocorticoids (Baird and 
Heitzman, 1971; Baird and Young, 1975; Butler and Elliot, 1970; Filsell et al., 1969) and 
growth hormone, which makes glucagon a better candidate for treatment of fatty liver. The 
glycogenolytic effect of glucagon can provide an instant source of glucose, the lower 
lipolytic rate will decrease the probability of a potential increase in concentration of NEFA 
in some animals, and the greater gluconeogenic effect will provide a more extended glucose 
supply. The beneficial effect of prostaglandin E, in sheep might be associated with the 
increased concentrations of plasma glucagon (Carruthers et al., 1974). The disadvantage of 
glucagon is that it does not promote VLDL secretion. An advantage and/or disadvantage of 
glucocorticoids is their anti-inflammatorv effect, which is beneficial because it suppresses 
inflammatory responses that are associated with fatty liver, but on the other hand 
glucocorticoids might counteract the treatment of diseases associated with fatty liver. The 
lack of success in treating fatty liver with growth hormone can be explained by its smaller 
effectiveness in the peripartal period. In summary, a combination of glucagon, insulin, and 
a glucose precursor might be the best combination to successfully treat most types of fatty 
liver. 
Rumen fermentation modifiers, such as monensin, chloral hydrate (2, 2, 2-trichloro-
1, 1-ethanediol), sodium chlorate, and potassium chlorate (T able s 11 and 12), shift rumen 
fermentation toward Gram-positive bacteria and propionate production, inhibit fermentation 
of carbohydrates and lactate and the production of methane, and are toxic for methanogenic 
bacteria (Prins and Seekles, 1968; Quaghebeur and Oyaert, 1971). Monensin, chloral 
hydrate, and sodium and potassium chlorate are effective because a) they shift the rumen 
microbial population from an acetate- to a propionate-producing fermentation, which is 
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doser to what is needed for the high concentrate rations after parturition, and b) they 
prevent infections by their bacteriocidal effect 
Table 13. Metabolic functions of hormones in comparison to fatty liver1. 
Metabolic Function Fatty 
Liver 
Glucagon Insulin Gluco­
corticoids 
Growth Hormone 
Hepatocytes: 
Gluconeogenesis 0 + — + + 
Glvcogenesis 2 
— + + 0 
Glycogenosis + + - 0 0 
Ketogenesis ± + - + + 
Lipogenesis + - + 0 0 
(3-Oxidation ± + - + + 
Protein synthesis 
— -
+ - + 
Proteolysis - ± - 0 0 
VLDL secretion - ± ± + + 
Adipocytes: 
Glucose uptake 0 ± + 0 0 
Lipogenesis 0 ± + 0 0 
Lipolysis + -f* - + + 
Lipoprotein lipolysis 0 ± + 0 0 
1 Adapted from page 108 Engelking (2000). 
2The symbols +, -, ±, and 0 mean increase, decrease, variable, and no effect. 
When the previously mentioned four rumen fermentation modifiers are compared, 
chloral hydrate is most effective, followed in potency by sodium and potassium chlorate 
(Table 11), because it is more toxic to Gram-negative bacteria. Monensin is a preventative 
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rather than a treatment (Table 12). Furthermore, chloral hydrate is an anesthetic, which can 
be used in cases of nervous ketosis. Chloral hydrate is the oldest treatment for ketosis 
(Shaw, 1956) but rarely is used in recent years. As preventative treatments, administration 
of humâtes, cellulose-lignin complexes, and yeasts are suggested (Furll. 2002; Stober and 
Scholz, 1991). Humâtes bind endotoxins, which are at elevated concentrations around 
calving. Cellulose-lignin complexes and yeasts stabilize the rumen population, and 
therefore, prevent rumen acidosis (Furll, 2002). If a cow has already rumen acidosis, 
administration of rumen fluid from healthy cows is recommended (Stober and Scholz, 
1991). 
Choleretic agents, antioxidants, vitamins, and amino acids primarily are used for 
prevention or to support treatment by hormones and glucose precursor. Clanobutin (Table 
12), dehydrocholic acid (Table 11), and ursodeoxycholic acid (not used in ruminants; Table 
14) increase bile flow, which is decreased because of compressed sinusoids in fatty liver 
(Furll, 1993; Karatzias et al., 1993; Symonds, 1982). Furthermore, all three interact with 
toxic bile acids such as deoxycholic acids, which are potent pro-oxidants and are cytotoxic 
at high concentrations (Hi 11 aire et al.. 1995; Mizoguchi et al., 1989). Thiopronine (i.e., 2-
mercaptopropionylglycine) is effective for supportive treatment of fatty liver (Table 12; 
Tanemura et al., 1986). Thiopronine uses its free thiol group for reducing reactions, as an 
antioxidant, and for binding to toxic compounds, thereby preventing mitochondrial 
dysfunction (Fuchs et al., 1985; Kami va et al., 2001; Zhang and Lindup, 1996). 
Supplementation with 5-10 mg selenium and «-tocopherol has been suggested also to prevent 
cellular damage by free radicals (Stober and Scholz, 1991). 
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Supplementation with vitamins and sulfur-containing amino acids can prevent fatty-
liver when these compounds are deficient (Table 12). Increased concentrations of sulfur-
containing amino acids can be achieved by supplementation of cysteamine-HCl or different 
forms of dietary methionine (Fox, 1971). Sulfur-containing amino acids, however, are 
cytotoxic at high concentrations (Kandylis, 1984). Supplementation of carnitine (Table 14) 
or its precursors, lysine and methionine, is effective when cows are deficient in lysine and/or 
methionine. Carnitine is involved in the interorganellar fatty acid transport in the liver 
(Bianchi et al., 1996; Sachan et al., 1984). Retinoic acid, biotin, choline, cyanocobalamin, 
niacin, and pantetheine are other vitamins that have been shown to cause fatty liver when 
they are deficient (Table 11 and 14). Therefore, a mixture of vitamins often is given as a 
prophylactic when cows are treated for fatty liver. 
Other compounds that are beneficial in the treatment of fatty liver are insulin-
sensitizing agents, for instance metformin, and inhibitors of lipolysis in the adipose tissue, 
for instance propanolol, a |3-receptor inhibitor (Aarsland et al., 1996), and sodium chloride 
(Furll, 2002; Tabic 14). Administration of anti-inflammatory agents such as sesame seed 
and fish oils (Chavali et al., 1997; Lanza-Jacoby et al., 1995; Moonev et al., 1998; 
Utsunomiya et al., 2000) are helpful in the treatment of fatty liver in non bovine species 
(Table 14). Other beneficial anti-inflammatory compounds are flumixin-meglumin, 
phenylbutazone, tea, and aspirin (Stober and Scholz, 1991). 
Besides these specific treatments, some general treatments need to be applied. Cows 
that are ill because of infectious or other metabolic disorders need to be treated additionally 
for their primary disease. The environment in which the diseased cow stays needs to be 
clean and disinfected and sufficiently ventilated with fresh air. If possible, the cows should 
34 
be moved outside for exercise at least one hour per day. To prevent decreased feed intake, 
diseased cows need access to fresh, high quality legume or grass hay. Other feeds that 
encourage cows that are off-feed to eat are calf feed, whole oats, coarsely ground horse feed, 
potato parings, and sliced apples (Fox, 1971). 
Table 14. Treatments of fatty liver in non-bovine species. 
Treatment Species Effect' Reference 
Biotin Chicken + Whitehead and Blair, 1976 
Branched-chain amino acids Rats +++ Kajiwara et al., 1998 
Carnitine Rabbits + Seccombe et al., 1987 
Carnitine Rats + Bianchi et al., 1996; Sachan et al., 1984 
Fish oil Rats + Lanza-Jacoby et al., 1995 
Metformin Mice +++ Lin et al., 2000 
Propanolol Sheep + Furll, 2002 
Prostaglandin Et Sheep ++ Carruthers et al., 1974 
Sodium chloride Sheep + Furll, 2002 
Ursodeoxycholic acid Rats ++ Oliva et al., 1998 
1 The number of + indicates slight, moderate, or strong effectivity as treatment of fatty liver. 
Glucagon 
Synthesis and Degradation of Glucagon. Glucagon is a 29 amino acid pancreatic 
peptide hormone that belongs to the glucagon superfamily, which include structurally similar 
regulatory peptides such as growth hormone-releasing hormone, vasoactive intestinal peptide, 
gastric inhibitory polypeptide, secretin, and pituitary adenylate cyclase activating protein 
(Heinrich et al., 1984). Glucagon is derived from preproglucagon, a 180 amino acid peptide 
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precursor that is deri ved of a single mRNA of 1400 nucleotides (Iieinrich et al., 1984). 
Beginning from the amino terminal end, preproglucagon consists of a signal peptide, 
glycentin-related polypeptide, glucagon, intervening protein 1. glucagon-like peptide-1, 
intervening protein 2, and glucagon-like peptide-2. Preproglucagon is expressed in brain, 
intestinal L cells, and pancreatic a cells. Preproglucagon is processed into proglucagon after 
the signal sequence has been cleaved off. In brain and intestinal L cells, proglucagon 
primarily is processed into glucagon-like peptides-1 and -2, whereas in the pancreas 
proglucagon primarily is processed into glucagon (Larsen et al., 1997; Mosjov et al., 1986; 
Rouillé et al., 1997a, b). The other proglucagon-derived peptides, in most cases, have minor 
physiological functions. Glucagon is highly conserved between species (Philippe, 1996). 
Glucagon can be further cleaved to mi ni glucagon in the pancreas or in target tissues (Carrey 
and Epand, 1983; Dalle et al., 1998). Glucagon and mini glucagon are mostly similar in their 
effect, whereas glucagon and glucagon-like peptide-1 differ in their effect (Dalle et al., 1998; 
Rouillé et al., 1997a, b; Sauvadet et al., 1996). 
Processing of glucagon is regulated by a cyclic AMP-depcndent pathway, protein kinase 
C, and prohormone convertase 1 and 2 (Drucker and Brubaker, 1989; Furuta et al., 2001 ; 
Yamato et al., 1990; Webb et al., 2002). Glucagon secretion is increased by cyclic AMP, 
epinephrine, leptin, and arginine and is decreased by glucagon, proglucagon-derived peptides, 
and insulin (Drucker and Brubacker, 1989; Goldstone et al., 2000; Kuhara et al., 1991; 
Philippe, 1998; Pipeleers et al., 1985; Yamato et al., 1990). The half-life of glucagon in 
bovine plasma is approximately 5 min (de Boer et al., 1986) before it is primarily degraded in 
liver (30-35%) and kidney (Brockman et al., 1976). The half-life of glucagon is not 
influenced significantly by diet or stage of lactation (Balage et al., 1984; de Boer et al., 1986). 
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Mechanism of Action of Glucagon. Glucagon exerts its effects by binding to cell-
surface receptors on target tissues. Glucagon receptors have been detected in liver, kidney, 
spleen, thymus, adrenal glands, pancreas, cerbral cortex, adipose tissue, lung, and 
throughout the gastrointestinal tract and are highest in liver and kidney (Dunphy et al., 1998; 
Foufelle et al., 1994; Svoboda et al., 1999;Yamato et al., 1997). Glucagon receptors are a 
63,000-D plasma membrane protein whose expression is strongly regulated (Nishimura et al., 
1996). Gluconeogenic and glycolytic substrates increase the expression of glucagon 
receptors, wherease glucagon and cAMP via feedback inhibition, and inhibitors of 
gluconeogenesis and glycolysis decrease the expression of glucagon receptors (Abrahamsen et 
al., 1995; Burcelin et al., 1998; Gill and Hart, 1981; Portois et al., 1999). 
Glucagon's main route of signal transduction is the adenylyl cyclase pathway. Binding 
of glucagon to its receptor activates a G$ protein and inhibits a Gj protein that, in turn, activate 
adenylyl cyclase. Adenylyl cyclase converts ATP to cAMP, which is converted to 5'-AMP 
by cAMP phosphodiesterase. Cyclic-AMP activates protein kinase A, which then 
phosphorylates various enzymes. A secondary route of signal transduction is the 
phospholipase C pathway. The binding of glucagon to its receptor activates a G protein that, 
in turn, activate phospholipase C. Phospholipase C converts phophatidylinositol 4,5-
bisphophate to inositol trisphosphate and 1,2-diacylglycerol, the later of which activates 
protein kinase C (Pittner and Fain, 1991; Tang and Houslay, 1992). Additionally the activated 
G protein and inositol trisphosphate open calcium channels and thereby increase 
concentrations of intracellular ionic calcium. Ionic calcium exerts its effect by a) binding to 
calmodulin, which activates calmodulin-dependent kinases, b) by binding to phospholipid, 
which activates phopholipid-dependent kinases, c) by binding to proteins, and/or d) by 
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increasing concentrations of ionic calcium in mitochondria and endoplasmatic reticulum 
(Hermsdorf et al., 1992; Hespeling et al., 1995; Mabrouk et al., 1998; Wheeler et al.. 1993). 
Both signal transduction pathways enable glucagon to regulate enzyme activity short-
term via phosphorylation and long-term via transcription. The primary target organs of 
glucagon are liver and kidney. As shown in Table 15, transcriptional regulation of gene 
expression is very important. Glucagon increases the expression of enzymes that increase 
gluconeogenesis, i.e., phosphoenolyruvate carboxykinase, pyruvate carboxylase, and serine 
dehydratase, which is needed to convert serine to pyruvate. A previous study from our group 
demonstrated that glucagon increases expression of pyruvate carboxylase in lactating dairy 
cows (She et al., 1999b), which supports results from sheep where glucagon increased the 
activity of pyruvate carboxylase (Brockman and Manns, 1973). Glucagon increases (3-
oxidation and ketogenesis by increasing expression of carnitine palmitoyltransferase-1 and 
lipoprotein lipase. Glucagon increases ureagenesis by increasing the expression of enzymes 
involved in the urea cycle, which are arginase, arginosuccinate lyase, arginosuccinate 
synthetase, carbamyl phosphate synthetase 1, ornithine/citrulline antiporter ORNT1, and 
ornithine transcarbamyla.se (Morris et al., 1987; Nebes and Morris, 1988). 
Glucagon also increases expression of insulin-like growth factor 1 and insulin-like 
growth factor binding protein -1 (Table 15), which arc both especially important for 
reproductive success. Glucagon also increases expression of nuclear factors such as hepatic 
nuclear factor 4a and protein kinases, such as mitogen-activated protein kinase that are 
important for signal transduction of glucagon. Glucagon increases glycogenolysis by 
phosphorylation of glycogen phosphorylase and inhibits glycogenesis by phosphorylation of 
glycogen synthetase (Aggarwal et al., 1995; Exton, 1987; Tan and Nuttal, 1993). Glucagon 
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increases tyrosine synthesis from phenylalanine hv activating phenylalanine hydroxylase by 
phosphorylation (Tipper and Kaufman, 1992) 
Table 15. Liver genes whose transcription is increased by glucagon. 
Gene 
Arginase 
Argi n i nosucci nate lyase 
Argininosuccinate synthetase 
Carbamyl phosphate synthetase 1 
Carnitine palmitoyltransferase-! 
Hepatic nuclear factor 4a 
Insulin-like growth factor-1 
Insulin-like growth factor binding protein-1 
Lipoprotein lipase 
Mitogen-activated protein kinase 
Ornithine/eitrulline antiporter ORNT1 
Ornithine transcarbamylase 
Phosphoenolpyruvate carboxykinase 
Pyruvate carboxylase 
Pyruvate dehydrogenase kinase 
Pyruvate dehydrogenase kinase activator 
protein 
Serine dehydratase 
Stearoyl coenzyme-A desaturase 1 
Reference 
Nebes and Morris, 1988; Morris et al., 1987 
Nebes and Morris, 1988; Morris et al., 1987 
Nebes and Morris, 1988; Morris et al., 1987 
Nebes and Morris. 1988; Morris et al., 1987 
Louet et al., 2001 
Oyadomari et al., 2000 
Kachra et al., 1991 
Kachra et al., 1991; Lee et al., 1993; 
McCarty, 1997 
Juive et al., 1996 
Schliess et al., 2000 
Morris and Kepka-Lenhart, 2002 
Morris et al., 1987 
Bratke et al., 1999; Casado et al., 1995; 
lynedjan et al., 1995; Rucktaschel et al.. 
2000 
She et al., 1999b 
Marchinglon et al., 1989 
Marchington et al., 1989 
Haas and Pitot, 1999 
Lefevre et al., 1999 
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Glucagon also decreases the expression of several enzymes (Table 16). Glucagon 
decreases glycolysis a) by decreasing expression of g!urokinase, 6-phosphofructo-2-
l(inase/fractose-2, 6-bisphosphatase, and pyruvate kinase, b) by decreasing the activity of 
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase and pyruvate kinase by phosphorylation 
(Exton, 1987), and c) by increasing the activity of fructose 1, 6 bisphophatase by 
phophorylation (Casteleijn et al., 1986; Ekdahl and Ekman, 1987). 
Table 16. Liver genes whose transcription is decreased by glucagon. 
Gene Reference 
Acetyl-CoA carboxylase Yin et al., 2000a 
ADDl/SREBP-lc1 Foretz et al., 1999 
Apoprotein E Andreani-Mangeney et al., 1996 
Fatty acid synthase Sul and Wang, 1998 
Glucokinase Iynedjian et al., 1989, 1995 
G1 ycerol -3-phosph ate acyltransferase Sul and Wang, 1998 
3-Hydroxy-3-methyl glutaryl-CoA Ness et al., 1994; Ness and Chambers, 2000 
reductase 
Leptin Ashwell et al., 1999 
Malic enzyme Goodridge et al., 1998 
6-Phosphofructo-2-ki nase/fructose- Casado et al., 1995 
2, 6-bisphosphatase 
3-Phosphogl ycerate dehydrogenase Achouri et al., 1999 
Pyruvate kinase Casado et al., 1995; Lou et al., 1999; Pan et al.. 
2000 
ADDl/SREBP-lc = adipocyte determination and differentiation factor 1/sterol regulatory 
clement binding protein-1c. 
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Glucagon inhibits synthesis of fatty acids and TAG at different steps of the pathway 
(Table 16). It inhibits synthesis of fatty acids by increasing expression of pyruvate 
dehydrogenase kinase and pyruvate dehydrogenase kinase activator protein, which inhibit 
synthesis of acetyl CoA. Fatty acid synthesis also is inhibited by glucagon by decreasing 
expression of acetyl-CoA carboxylase and fatty acid synthase probably by inhibiting 
transcription factor adipocyte determination and differentiation factor 1/sterol regulatory 
element binding protein-lc (ADD 1/SREBP-lc; Foret/ et al., 1999). Inhibition of malic 
enzyme by glucagon decreases fatty acid synthesis because malic enzyme catalyzes the 
reaction that produces NADPH, the source of reducing potential for fatty acid synthesis. 
Glucagon decreases glycerol synthesis by decreasing expression of 3-phosphoglycerate 
dehydrogenase, and it decreases synthesis of TAG by inhibiting expression of glycerol-3-
phosphate acyltransferase. 
Metabolic Effects of Glucagon. The effects of glucagon on enzyme concentrations and 
activities cause increases in gluconeogenesis, [3-oxidation, ketogenesis, glycogenolysis, and 
ureagenesis and decreases in synthesis of TAG and VLDL secretion in hepatocytes (Table 
17). In adipocytes, glucagon decreases lipogenesis and increases lipolysis, but the effects are 
counteracted by increased concentrations of plasma insulin and glucose after glucagon. In the 
case when concentrations of plasma insulin are not increased by glucagon infusion, glucagon 
increases concentrations of plasma NEFA via increased lipolysis in adipose tissue and 
concentrations of plasma BHBA via increased ketogenesis in the liver (Brockman, 1976, 
1978; Brockman et al., 1975). Lipogenesis in the mammary gland is not affected by glucagon 
(Jones et al.. 1984; Robson et al., 1984). 
41 
Table 17. Effect of glucagon on metabolic function in hepatocytes and adipocytes. 
Pathway Species Effect1 Reference 
Hepatocytes: 
Gluconeogenesis 
Glycogenosis 
Glycogenesis 
Ketogenesis 
Ketogenesis 
f3-Oxi dation 
Oxidative phosphorylation 
Triacylglycerol synthesis 
Transamination 
Ureagenesis 
VLDL secretion 
Adipocytes: 
Lipogenesis 
Lipolysis 
Bovine +++ Atwal and Sauer, 1973; Cardorniga-
Valino et al., 1997; Donkin and 
Armentano, 1995; Zhu et al., 1997 
Bovine +++ Morand et al., 1988, 1990 
Bovine - Donkin and Armentano, 1995 
Bovine 0 Cardorniga-Valino et al., 1997 
Rat + Bjornsson et al., 1992; Zupke et al., 1997 
Bovine - Atwal and Sauer, 1973 
Bovine - Atwal and Sauer, 1973 
Bovine Cardorniga-Valino et al., 1997 
Bovine +++ Zhu et al., 1997 
Bovine ++ Strang et al., 1998a; Zhu et al. 1997, 2000 
Rats - Beynen et al., 1981; Bjornsson et al., 
1994; Duerden and Gibbons, 1993 
Rat - Foufelle et al., 1994 
Bovine + Metz and van den Bergh, 1977 
1 The symbols +, -, and ± mean increase, decrease, and variable effect, respectively, and the 
number of symbols represents slight, moderate, or strong effect; 0 means no effect. 
Glucagon counteracts almost all detrimental metabolic effects of fatty liver (Table 5) 
except that VLDL secretion is decreased. VLDL secretion, however, is not decreased in 
fasted animals (Guettet et al., 1991), which is a state similar to cows with fatty liver, because 
VLDL secretion is driven primarily by synthesis of TAG in the liver (Beynen et al., 1981). 
Glucagon probably adjusts VLDL synthesis, packaging, and secretion to the amount of liver 
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TAG available (Beynen et al., 1981 ; Pullinger and Gibbons, 1985). The most likely 
mechanisms are that glucagon increases LDL-uptake and degradation (Brown et al., 1989; 
Rudling and Angelin, 1993) and decreases synthesis of apoprotein E, which is primarily in the 
HDL and LDL fractions ( Andreani -M an gene y el aL 1996; Guettet et al., 1991). 
Glucagon increases gluconeogenics by promoting conversion of amino acids into 
glucose (Brockman and Greer, 1980). Glucagon primarily increases hepatic uptake of 
alanine, asparaginc, glycine, histidine, lysine, methionine, phenylalanine, serine, threonine, 
and tyrosine. It does not affect the uptake of branched-chain amino acids whose 
concentrations are decreased in cows with fatty liver. The amino acids are then degraded, 
involving transamination as one step, and converted into glucose (Boden et al., 1990; 
Brockman et al., 1975; Flakoll et al., 1994). Glucagon increases blood flow by its 
vasodilative effect (Brockman, 1976, 1978; Brockman et al., 1975), which partly might 
explain the choleretic effect of glucagon (Dyck and Janowitz, 1971). Furthermore, glucagon 
decreases the incidence of viral infections by inhibiting replication of viruses (Hild et al., 
1998). 
Injection and infusions of glucagon affect the composition of liver, plasma, and milk 
(Tables 18 and 19). Glucagon increases concentrations of plasma glucose by promoting 
degradation of glycogen and utilization of plasma amino acids for gluconeogenesis. which 
decreases concentrations of liver glycogen (Table 18) and milk protein (Table 19). 
Concentrations of li ver glycogen decrease for the first few days of glucagon infusion and then 
increase because of the elevated concentrations of plasma insulin and glucose. The increase in 
concentrations of glycogen persists for several days after infusion of glucagon is terminated, 
indicating a form of regulation that is slow and persistent. The change in concentration of 
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glycogen is the only change in any of the metabolic parameters that persisted after period of 
glucagon administration ended (Hippen et al., 1999b; She et al., 1999b). 
Table 18. Effect of glucagon on concentrations of liver and plasma constituents in lactating 
dairy cows. 
Constituent Effect1 Reference 
Liver: 
Glycogen 
Triacylglycerol 
Plasma: 
BHBA 
Glucagon 
Glucose 
Insulin 
NEFA 
Urea N 
± Hippen et al., 1999b; She et al., 1999a, b 
Hippen et al., 1999b; She et al., 1999a 
0 Hippen et al., 1999a, b; She et al., 1999a, b 
+++ de Boer et al., 1986; Hippen et al., 1999a, b; Holtenius and 
Trâvén, 1990; Holtenius et al., 1998; She et al., 1999a, b 
+ de Boer et al., 1986; Hippen et al., 1999a, b; Holtenius, 1991; 
Holtenius and Trâvén, 1990; Holtenius et al., 1998; She et al., 
1999a, b; Steen et al., 1997; Trevisi et al., 1997a 
+ de Boer et al., 1986; Hippen et al., 1999a, b; She et al., 1999a, 
b; Steen et al., 1997 
± de Boer et al., 1986; Hippen et al., 1999a, b; She et al., 1999a, b 
0 Hippen et al., 1999a, b; She et al., 1999a, b 
T The symbols +, -, and ± mean increase, decrease, or variable effect, and the number of 
symbols represents slight, moderate, or strong effect; 0 means no effect. 
Concentrations of plasma glucose reach peak, values about one hour after glucagon is 
injected and then begin to decrease (Holtenius. 1991; Holtenius and Trâvén, 1990; Holtenius 
et al., 1998; Steen et al., 1997). The exceptions are about 20% of cows with fatty liver, 
ketosis, and displaced abomasum, which show signs of type II diabetes and are not able to 
transport glucose into peripheral tissues (Holtenius, 1991; Holtenius and Trâvén, 1990; 
Holtenius and Holtenius, 1996; Holtenius et al., 1998; Steen et al., 1997). The response of 
insulin to injections of glucagon in cows with metabolic diseases is extremely variable. 
Concentrations of insulin are either very high or are not increased at all, which means that 
these cows probably also have increased concentrations of NEF A and BHBA after injections 
of glucagon, because elevated concentrations of insulin and glucose cannot counteract the 
increased lipolysis induced by administration of glucagon. The variable response of plasma 
insulin to injections of glucagon can explain why concentrations of plasma NEFA are 
sometimes increased but at other times are decreased. In previous studies, instead of greater 
variability either a small or no increases in concentrations of plasma insulin of cows with fatty 
liver were observed (Hippen et al., 1999a, b; She et al., 1999a, b). The decreased response of 
insulin concentrations to glucagon can be explained by concentrations of glycogen in the 
pancreas being insufficient to induce insulin secretion (Malaisse et al., 1990, 2001). 
Concentrations of liver TAG were decreased in cows that had elevated concentrations of 
liver TAG before infusion of glucagon but had no effect in cows with normal concentrations 
of liver TAG (Table 18; Hippen et al., 1999b, She et al., 1999a). There are three possible 
reasons for the difference in response: First, the concentrations of liver TAG in normal cows 
was already at baseline concentrations, thus glucagon could not further decrease 
concentrations of liver TAG. Second, younger cows, which were primarily in the normal liver 
group, react differently to glucagon than do older cows, which were primarily in the fatty liver 
group. Third, cows with fatty liver that were infused with glucagon might have received more 
energy than did cows with fatty liver that were treated with saline, because glucagon-treated 
cows received more 1,3-butanediol, which could have been used as an additional energy 
source during feed-restriction that lasted throughout the period of glucagon infusion. 
Concentrations of BHBA and urea N were not affected significantly by glucagon 
infusions (Table 18). The lack of an effect of glucagon on concentration of BHBA can be 
explained by the high proportion of plasma BHBA that is of dietary origin from butyrate 
absorbed from the rumen. Another explanation is that glucagon directly increases ketogenesis 
but indirectly decreases ketogenesis via increasing concentrations of plasma insulin and 
glucose. Concentrations of plasma urea N were not affected by glucagon, which also is 
documented for sheep. The lack of response is surprising because glucagon increases 
ureagenesis and, in contrast to that in monogastrics, ruminants have a decreased urine flow 
and glomerular filtration rate and a decreased secretion of electrolytes and urea N after 
infusion of glucagon (Faix and Leng, 1997). The only possible explanation is that excess urea 
N is secreted into the rumen. 
Glucagon infusions decreased feed intake in dairy cows (Table 19), which can be 
explained by the fact that glucagon increases the turnover time of abomasal fluid either 
directly and/or indirectly by increasing concentrations of plasma insulin and glucose 
(Holtenius et al., 1998; van Meirhaeghe et al., 1988). Decreased feed intake also might 
explain the decrease in milk production, because both effects were associated strongly with 
each other. The increase in concentration of milk fat could be a response to the decrease in 
milk production. Glucagon increased concentrations of milk lactose only during the first few 
days of the infusion period, which might be related to the increased availability of glucose. 
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Table 19. Effect of glucagon on dry matter intake and milk production and composition in 
lactating dairy cows. 
Constituent Effect' Reference 
Dry matter intake 
-
Hippen et al., 1999b; She et al., 1999a 
Milk: 
Amount - Hippen et al., 1999a, b; She et al., 1999a: Trevisi et al., 
1997a 
Fat percentage + Hippen et al., 1999a, b; She et al., 1999a; Trevisi et al., 
1997a 
Lactose percentage + Hippen et al., 1999b; She et al., 1999a; 
Protein percentage Hippen et al., 1999a, b; She et al., 1999a; Trevisi et al., 
1997a, b 
1 The symbols + and - mean increase and decrease, respectively, and the number of symbols 
represents slight, moderate, or strong effect. 
Limitations of Glucagon as a Treatment of Fatty Liver. The limitation for the use of 
glucagon to prevent fatty liver is its variable effect on concentrations of insulin. If glucagon 
administration does not increase concentrations of insulin, which can be called glucagon 
resistance, it is very likely that glucagon increases instead of decreases concentrations of 
plasma NEFA and BHBA, which are part of the etiology of fatty liver. Administration of 
glucagon alone probably cannot be fully effective in cows that develop diabetes, because the 
limited uptake of energy precursors by peripheral tissues will not be increased by increasing 
concentrations of plasma glucose via glucagon. For treatment of glucagon-resistant and 
diabetic cows, treatment with a combination of glucagon and insulin in a slow-release form is 
recommended. In cows with subclinical fatty liver, instead of insulin injections an 
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insulinotropic diet can be used to increase concentrations of plasma insulin (Gong et al., 
2002). Cows whose primary cause for fatty liver is associated with inflammation are more 
likely to receive relief from glucocorticoids than from glucagon, because glucocorticoids are 
anti-inflammatory. 
Another group of cows that would not benefit from glucagon are those that have limited 
glucose precursors for gluconeogenesis, for example starving animals (Burtis et al., 1968). 
Such cows primarily need glucose precursors, which glucagon can provide only to a limited 
degree through degradation of endogenous amino acids and glycogen. When concentrations 
of plasma amino acids and liver glycogen are low, the capability of glucagon to supply 
enough glucose for uptake in peripheral tissues is limited. For treatment of starving cows, 
combining treatment of glucagon with a gluconeogenic precursor is recommended. 
Summary. 
Fatty liver is a 'hidden, abating' disorder that occurs in nearly 50% of all dairy cows 
in the peripartal period. It costs US-farmers millions of dollars yearly because of increased 
veterinary and insemination costs, longer calving intervals, and decreased average lifetime 
of cows in its subclinical form. In the clinical form that occurs in 5-10% of all dairy cows, 
fatty liver can result in the death of nearly 25% of all affected animals despite treatment. 
Fatty liver develops primarily in the metabolically and physiologically challenging 
periparturient period because of insufficient nutrient uptake, hormonal changes, diseases, 
and greater incidences of infections, inflammations, and stress, and/or genetic 
predisposition. Often, fatty liver is 'hidden' because the cow is producing and eating well, 
but its nonobvious detrimental metabolic effects on the function of liver and other organs 
eventually affect the health status and reproductive performance for months after TAG 
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infiltration subsides. Therefore, it is imperative that fatty liver is treated immediately by 
counteracting the deficiencies that caused the lipid infiltration in the first place. 
The treatment of fatty liver depends on the extent of lipid infiltration and the 
etiology. In severe cases, intravenous administration of a simple carbohydrate combined 
with hormonal treatment using slow-release insulin and glucagon or glucocorticoids is 
recommended until the dietary intake becomes sufficient to satisfy metabolic needs. 
Administration of glucagon should be preferred over glucocorticoids because of the more 
broad-ranging beneficial metabolic effects of glucagon (Bassett, 1970). In less severe cases, 
oral administration of glucose precursors and/or treatment with glucocorticoids or glucagon 
in conjunction with treatment or elimination of the primary cause for fatty liver is 
recommended. Prevention of fatty liver, however, by supplying cows with enough nutrients 
and a clean, health-promoting, and nonstressful environment in the periportal period, will be 
always better than any treatment for their future health status and reproductive performance. 
Conclusion. 
The objective of this review was to give an overview about the pathology and etiology 
of fatty liver and then to describe and compare different treatments. The review 
demonstrates that there is an economic incentive to treat and/or prevent fatty liver because 
the incidence of fatty liver is very high in the general population of dairy cows and because 
of its detrimental effects even in subclinical diseased cows. Clearly, there is not one cause 
for fatty liver. Therefore, the choice of treatment depends on the specific etiology of fatty 
liver of the individual cow. Treatment of the primary cause of fatty liver combined with 
administration of a glucose precursor and glucagon seems to be the best option for most 
types of fatty liver. 
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METABOLIC RESPONSES OF LACTATING DAIRY COWS TO 
SINGLE AND MULTIPLE INJECTIONS OF GLUCAGON 
A paper submitted to the Journal of Dairy Science 
Gerd Bobe, Roberto N. Sonon, Burim N. Ametaj, Jerry W. Young, and Donald C. Beitz 
Abstract 
Continuous, intravenous infusions of glucagon improve carbohydrate status in lactating 
dairy cows without increasing concentrations of plasma NEF A. The objective was to test 
whether single subcutaneous injections and multiple injections of 2.5 and 5 mg of glucagon 
over 14 d improve the carbohydrate status in lactating dairy cows without increasing 
concentrations of plasma BHBA and NEFA. In a single-injection experiment, four 
midlactation cows each were injected with 2.5 and 5 mg of glucagon one wk apart. In a 
multiple-injection experiment, nine cows, assigned randomly to three treatments, were 
injected subcutaneously with 0, 2.5, or 5 mg of glucagon every 8 h for 14 d, beginning at d 8 
postpartum. Both single and multiple subcutaneous injections of glucagon increased 
concentrations of plasma glucagon (measured in the single-injection experiment only) and 
glucose, with larger increases at the 5-mg dosage. Injections of 5 mg of glucagon increased 
concentrations of plasma insulin in both experiments, whereas the 2.5-mg dosage increased 
plasma insulin in the multiple-injection experiment only. The response of glucose and 
insulin to injections of 5 mg of glucagon persisted throughout the 14-d injection period. 
Concentrations of plasma NEFA decreased in the single-injection experiment, and 
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concentrations of BHBA decreased after 5 mg of glucagon was injected in the multiple-
injection experiment. These results document that both single and multiple injections of 5 
mg of glucagon over 14 d consistently improve the carbohydrate status of dairy cows and 
decrease concentrations of plasma NEFA and BHBA. 
Introduction 
Fatty liver (i. e., hepatic lipidosis) is one of the major metabolic disorders of dairy cows 
in the peripartal period, which affects up to 50% of cows in early lactation (Jorritsma et al., 
2001). Fatty liver can negatively affect the productivity, health status, and reproductive 
performance of high-producing dairy cows (Bobe et al., 2003b; Herdt, 1988; Veenhuizen et 
al., 1991; Wensing et al., 1997) and can be treated with continuous, intravenous infusions of 
glucagon for 14 d (Hippen et al., 1999b). 
Administration of exogenous glucagon increases concentrations of plasma glucagon, 
glucose, and insulin in lactating dairy cows (de Boer et al., 1986; Hippen et al., 1999b; She 
et al., 1999; Trevisi et al., 1997) by stimulating hepatic gluconeogenesis, glycogenolysis, 
amino acid uptake, and ureagenesis (Donkin and Armentano, 1995; Flakoll et al., 1994). 
The metabolic response to glucagon depends on the dosage and the age, stage of lactation, 
and health of cows, with weaker responses at lower glucagon dosages in older, ketotic cows 
in early lactation (Bobe et al., 2003a; de Boer et al., 1986; Hippen et al., 1999a, h; Holtenius 
and Holtenius, 1996; Holtenius and Trâvén, 1990; She et al., 1999; Steen et al., 1997). 
The effects of glucagon on concentrations of plasma BHBA and NEFA can be both 
direct and indirect because glucagon directly increases lipolysis and ketogenesis (Brockman, 
1976; Zupke et al., 1998) but indirectly decreases lipolysis and ketogenesis by increasing 
concentrations of plasma glucose and insulin (Brockman, 1978). Therefore, glucagon can 
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either increase or decrease concentrations of plasma BHBA and NEFA depending on 
responses of glucose and insulin, dosage of glucagon, and age, stage of lactation, and health 
of the cow, with increases being more likely at higher glucagon dosages in younger, ketotic 
cows in early lactation (Bobe et al.. 2003a; de Boer et al., 1986; Hippen et al.. 1999a, b; She 
et al., 1999). 
The metabolic response to glucagon also is influenced by the mode of application. 
Pulsatile glucagon delivery, which is similar to multiple injections, increases hepatic 
glucose production more effectively than does continuous delivery and more closely 
resembles the release of glucagon by the pancreas (Lefèbvre et al., 1996). We demonstrated 
previously that the insulin response decreases during continuous infusions of glucagon 
(Hippen et al., 1999b; She et al., 1999) but not during multiple injections of glucagon (Bobe 
et al., 2003a). Intravenous infusions of glucagon result in greater responses than do 
subcutaneous injections (Muhlhauser et al., 1985), which is similar to results obtained in our 
laboratory (Bobe et al., 2003a; Hippen et al., 1999a, b; She et al., 1999); however, long-term 
intravenous infusions of glucagon are not practical for on-farm use. 
Therefore, the current objective was to determine whether single subcutaneous 
injections of glucagon and multiple injections every 8 h over 14 d consistently improve the 
carbohydrate status in lactating dairy cows without increasing concentrations of plasma 
BHBA and NEFA. More specifically, the objective was to determine the effects of 
subcutaneous injections of 2.5 and 5 mg of glucagon on concentrations of plasma glucagon, 
glucose, insulin, BHBA, and NEFA over a 14-d injection period. 
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Materials and Methods 
Experimental Design. Parts of the experimental design and several of the 
experimental techniques and methods have been described in detail elsewhere (Bobe et al., 
2003a). Muciparous Holstein cows housed in a tie-stall barn were used in both 
experiments. They had free access to a typical NRC-recommended (2001 ) TMR for high-
producing cows that was offered daily at 8:00 and 18:00. The ration consisted primarily of 
corn, alfalfa hay, cottonseed, and soybean meal and contained 1.72 Mcal/kg NEL, 16.8% 
CP, 16.5% ADF, and 29% NDF (Bobe et al., 2003a). 
Using a latin square design for the single-injection experiment, four midlactation cows 
were injected subcutaneously at 10:00 with either a single dosage of 2.5 (2.5 mg) or 5 (5 
mg) mg of lyophilized bovine glucagon (donated by Eli Lilly & Co., Indianapolis, IN) 
followed 1 wk later by the other dosage. The glucagon was dissolved before injection in 60 
ml of 0.15 M NaCl (final pH 10.25). By using a completely randomized design for the 
multiple-injection experiment, nine cows (three cows per treatment) were injected 
subcutaneously with 0 (Saline), 2.5 (2.5 mg), or 5 mg (5 mg) glucagon in 60 ml of 0.15 M 
NaCl every 8 h (6:00, 14:00, and 22:00) for 14 d beginning at 14:00 of d 8 postpartum 
(Bobe et al., 2003a). Blood samples were collected after glucagon injections on d 1 at 14:00 
(Dl-14:00), on d 1 at 22:00 (Dl-22:00), on d 7 at 14:00 (D7-14:00), and on d 13 at 14:00 
(D13-14:00). All cows were managed and treated in accordance with guidelines established 
by the Iowa State University Committee on Animal Care. 
Sampling and Analysis. For blood collection, a catheter (Angiocath™, 22.1 x 133 
mm; Becton Dickinson Infusion Therapy Systems Inc., Sandy, UT) was inserted into the 
jugular vein. Prior to catherization, the area was disinfected, shaved, and anesthetized with 
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an injection of 10 ml of Xylocaine® (lidocaine hydrochloride, 2%; Med. Tech. Inc., 
Elkwood, KS). In both experiments, blood was collected at -15, -10, -5, 15. 30,45, 60, 80, 
100, 120, 150,180, 210, 240, 300, 360, 420, and 480 min after glucagon injections into 10-
ml Vacutainer® tubes (Beckton Dickinson and Co., Rutherford, NJ) that contained Na%-
EDTA in the single-injection experiment and Kg-EDTA in the multiple-injection 
experiment. The first three samples were used to establish a baseline. Between samples, 
catheters were kept patent by injecting 5 ml sodium citrate (1% sodium citrate in 0.15 M 
NaCl) into the catheter. The catheter and catheterization site were changed after each 
injection period except for the two d-1 injections in the multiple-injection experiment. 
Plasma samples were prepared by centrifligation within 20 min after blood collection 
and stored in polystyrene or glass (for glucagon analysis) tubes at -20 °C until analysis. 
Plasma samples were analyzed for concentrations of glucagon (glucagon kit number 
KGND1 ; Diagnostic Products Corp., Los Angeles, CA), glucose (glucose kit number 315; 
Sigma, St. Louis, MO), insulin (insulin kit number TKIN; Diagnostic Products Corp., Los 
Angeles, CA), NEFA (NEFA-C kit number 994-75409; WAKO, Richmond, VA), and 
BHBA (kit number 310-A; Sigma, St. Louis, MO). Before storage of samples, aprotinin 
(Boehringer-Mannheim, Indianapolis, IN) was added at 500 KIU to 1 ml of plasma samples 
intended for glucagon analysis. Unfortunately, Kj-EDTA interfered with analysis of 
glucagon samples and. therefore, glucagon concentrations cannot be reported for the 
multiple-injection experiment. 
Statistical Analysis. Data from both experiments were analyzed as a double repeated 
measures study by using the mixed models procedures of SAS Version 8.2 (2001). The 
response variable was the change from the average concentration of the three baseline 
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samples before injection except for plasma insulin response in the single-injection 
experiment and NEFA response in the multiple-injection experiment, where the changes 
were calculated from the logarithmic concentrations of their respective concentrations in 
plasma. The average response for the 8-h post-injection period was calculated as the area 
under the curve minus the area below the baseline concentration by using the trapezoidal 
rule divided through 480 min. 
In the single-injection experiment, the fixed effects were treatment (2.5 mg or 5 mg), 
time after injection (15,30,45,60, 80,100,120,150,180, 210,240,300, 360,420, or 480 
min). and treatment by time after injection interaction. In the multiple-injection experiment, 
the fixed effects were treatment (Saline, 2.5 mg, or 5 mg), day and time of injection (Dl-
14:00, Dl-22:00, D7-14:00, or D13-14:00), time after injection (same as in the single-
injection experiment), and all their two-way and three-way interactions. For both 
experiments, the Kronecker product of a completely unrestricted (for treatment in the single-
injection experiment and for day and time of injection in the multiple-injection experiment) 
and a first order autoregressive (for time after injection) variance-covariance structure was 
used to account for correlations and changes in variances for repeated measures taken on 
individual cows across time. For the average response of the 8-h post-injection period, time 
after injection was not included in the statistical model. 
The effects of 2.5 mg and 5 mg of glucagon were evaluated by using the ESTIMATE 
statement. In the single-injection experiment their estimated means were evaluated without 
any further adjustments, and in the multiple-injection experiment their estimated means 
were compared with the estimated mean of the Saline group. The Satterthwaite 
approximation for degrees of freedom with a Kenward-Roger adjustment on standard errors 
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was invoked with the KENVVARDROGER option for degrees of freedom. Means and 
SEM s  p resented in figures are raw means and SEMs. Significance was declared at P < 0.05. 
Results 
To characterize the responses of plasma parameters to single and multiple injections of 
2.5 and 5 mg of glucagon for the 8-h post-injection period, three parameters were used: 
overall, average, and duration of response. The overall response is defined as the overall 
change for the 8-h post-injection period, whereas the average response is defined as the 
average change during the 8-h post-injection period and is not shown in the Figures. 
Duration of response is defined as the time during which concentrations were significantly 
different at P < 0.05. 
Single-Injection Experiment. In the single-injection experiment, concentrations after 
glucagon injections were compared to those before injections. Single subcutaneous 
injections of 2.5 and 5 mg of glucagon increased plasma glucagon (both P < 0.0001; Figure 
1A), with an average response for the 8-h post-injection period of 92 ±17 (P < 0.03) at the 
2.5- and 206 ± 43 pg/ml (P < 0.04) at the 5-mg dosage. The overall response of plasma 
glucagon was larger at the 5-mg dosage (P < 0.002; Figure I A ). Concentrations of plasma 
glucagon were increased significantly for the first 4 and 3 h after the injection of 2.5 and 5 
mg of glucagon, respectively, with a stronger increase for the first 2 h at the 5-mg dosage 
(Figure 1A). The fact that the duration of the response was shorter at the 5-mg dosage, 
although raw means of plasma glucagon were higher at the 5-mg dosage (Figure 1A), can be 
explained by greater variation of responses of plasma glucagon. 
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Figure 1. Réponses of plasma glucagon, glucose, insulin, and NEFA concentrations to 
single, subcutaneous injections of 2.5 and 5 mg of exogenous glucagon in four 
midlactation, multiparous dairy cows during the 8-h post-injection period. A. Response 
of plasma glucagon to 2.5 mg (P < 0.0001) and 5 mg of glucagon (P < 0.0001) and 
difference in response (P < 0.002). Concentrations were increased significantly for 4 (2.5 
mg) and 3 h (5 mg), with greater increases for the first 2 h after injection of 5 mg of 
glucagon. B. Response of plasma glucose to 2.5 mg (P < 0.002) and 5 mg of glucagon (P 
< 0.0001) and difference in response (P < 0.0001). Concentrations were increased 
significantly for 2 (2.5 mg) and 5 h (5 mg), with greater increases for the first 3 h after 
injection of 5 mg ofglucagon. C. Response of plasma insulin to 2.5 mg (P < 0.72) and 5 
mg of glucagon (P < 0.05) and difference in response (P < 0.22). Concentrations were 
increased significantly for 1 (2.5 mg) and 2.5 h (5 mg), with no significant differences 
between dosages. D. Response of plasma insulin to 2.5 mg (P < 0.06) and 5 mg of 
glucagon (P < 0.03) and difference in response (P < 0.90). Concentrations were not 
affected significantly by 2.5 mg of glucagon, decreased significantly for 4 h after injection 
of 5 mg of glucagon, and were significantly greater at 8 h after injection of 5 mg of 
glucagon. 
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The response of plasma glucose and glucagon to single injections of glucagon was 
similar (Figure 1). Plasma glucose concentrations were increased overall by subcutaneous 
injections of 2.5 (P < 0.007) and 5 mg of glucagon (P < 0.0001), with a stronger increase at 
the 5-mg dosage (P < 0.0001; Figure IB). The average response for the 8-h post-injection 
period was 4.3 ± 0.9 (P < 0.02) for 2.5 and 14.1 ± 2.7 mg/dl (P < 0.01) for 5 mg of glucagon 
injected. Concentrations of plasma glucose were increased significantly for the first 2 and 4 
h after injections of 2.5 and 5 mg of glucagon, respectively (Figure IB). 
The shape of the response of plasma insulin, glucagon, and glucose to single injections 
of glucagon were similar (Figure 1), but the response of insulin was smaller than responses 
of plasma glucagon and glucose because concentrations of insulin decreased below baseline 
at 4 h after the injection (Figure 1C). Subcutaneous injections of 5 mg of glucagon (P < 
0.05) but not injections of 2.5 mg of glucagon (P < 0.72) increased overall concentrations of 
insulin. Concentrations of plasma insulin were increased significantly for 1 and 2.5 h after 
injection of 2.5 and 5 mg glucagon, respectively (Figure 1C). 
Subcutaneous injections of both 2.5 and 5 mg of glucagon decreased overall plasma 
NEFA concentrations at P < 0.06 and P < 0.03, respectively, with significant decreased 
concentrations for the 4 h at the 5-mg dosage but not at the 2.5-mg dosage (Figure ID). The 
pattern of responses of plasma NEFA to single injections of glucagon were mirror images of 
responses of glucagon, glucose, and insulin, except that the rates of decrease were less steep 
and more persistent and concentrations of NEFA increased at 7-8 h post injection (Figure 1 ). 
Multiple-Injection Experiment. In the multiple-injection experiment, responses to 
glucagon injections in the 8-h post-injection period were compared with those after saline 
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injections. For time and day-of-injection effects, data from responses to multiple injections 
of 5 mg of glucagon on Dl-14:00, D1-22:00, D7-14:00, and D13-14:00 were used. Single 
and multiple subcutaneous injections of glucagon affected concentrations of plasma glucose 
in a similar way (Figures IB versus 2A and B). The only differences in the multiple-
injection experiment were that baseline concentrations of glucose were lower (55 in 
comparison to 73 mg/dl; Figures IB and 2A) and that concentrations of glucose were 
increased less after injections of glucagon (6.6 ± 2.1 mg/dl at the 2.5-mg dosage and 3.6 ± 
2.1 mg/dl at the 5-mg dosage). Multiple subcutaneous injections of glucagon increased 
overall concentrations of glucagon after injections during the 14-d injection period at both 
dosages (P < 0.002 for 2.5 mg and P < 0.0001 for 5 mg), but the increase was larger at the 
5-mg dosage (P < 0.02; Figure 2A). Multiple injections of glucagon significantly increased 
concentrations of plasma glucose for the first 2 (2.5 mg) and 4 h (5 mg) after injections 
during the 14-d injection period, and the increase was larger for the first hour after injection 
of the 5-mg dosage (Figure 2A). 
Day and time of glucagon injection both affected the response of plasma glucose to 
multiple injections of 5 mg of glucagon (Figure 2B). The overall response of glucose was 
larger after injection of 5 mg of glucagon at 14:00 on d 1, 7, and 13 (P < 0.0001, P < 0.004, 
and P < 0.0001 ) than at D 1-22:00 (P < 0.54; Figure 2B), which caused a time of injection 
interaction on d 1 (P < 0.02). The average response of glucose to injections of 5 mg of 
g l u c a g o n  f o r  t h e  8 - h  p o s t - i n j e c t i o n  p e r i o d  i n c r e a s e d  n u m e r i c a l l y  f r o m  6 . 6  ±  4 . 9  m g / d l  ( P  <  
0.23) on D 1-14:00 to 10.7 ±3.1 mg/dl (P < 0.01 ) on D13-14:00 and concentrations of 
glucose remained elevated significantly longer (2 h at Dl-14:00 in comparison to 4 h at 
59 
85-
5mg 
-DMtOO 
-01-22:00 
-D7-14:00 
-013-14:00 
80-
65-
60-
55-
50-
0 1 2 3 4 5 6 7 8 
80-
65-
60-
0 1 2 3 4 5 6 7 8  
TimePûstlrçection(h) Time Post Injection (h) 
—V—5mg 
—A—25rrg 
10-
i 
c 
1 
c 
0 1 2 3 4 5 6 7 8  
16, 
5mq 
-01-14:00 
-01-22:00 
-07-14:00 
-013-14:00 
c 10 
0 1 2 3 4 5 6 7 8  
Time Post Injection (h) Time Post Injection (h) 
Figure 2. Responses of plasma glucose and insulin concentrations to multiple, 
subcutaneous injections of 2.5 and 5 mg of exogenous glucagon every 8 h for 14 d in 
early lactation, muciparous dairy cows (n = 3 in each treatment group) during the 8-h 
post-injection periods. A. Overall response of plasma glucose to 2.5 mg (P < 0.002) and 
5 mg of glucagon (P < 0.0001) and difference in response (P < 0.02) over the 14-d 
injection period. Concentrations were increased significantly for 2 (2.5 mg) and 4 h (5 
mg), with greater increases for the first hour after injection of 5 mg of glucagon. B. 
Response of plasma glucose to 5 mg of glucagon on D 1-14:00 (P < 0.0001), D1 -22:00 (P 
< 0.54), D7-14:00 (P < 0.004), and D 13-14:00 (P < 0.0001). Concentrations were 
increased significantly for 2 h on D 1 -14:00 and D7-14:00 and 4 h on D 1 3-14:00 and were 
not affected significantly on Dl-22:00. C. Overall response of plasma insulin to 2.5 mg 
(P < 0.03) and 5 mg of glucagon (P < 0.0002) and difference in response (P < 0.06) over 
the 14-d injection period. Concentrations were increased significantly for 2 (2.5 mg) and 
3 h (5 mg), with greater increases for the first h after injection after injection of 5 mg of 
glucagon. D. Response of plasma insulin to 5 mg of glucagon on D 1-14:00 (P < 0.01), 
Dl-22:00 (P < 0.15), D7-14:00 (P < 0.05), and D13-14:00 (P < 0.03). Concentrations 
were increased significantly for 2 h on D 1 -14:00 and D7-14:00 and 3 h on D 13-14:00 and 
were not affected significantly on D 1-22:00. 
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D13:14:00; Figure 2B). The greater variation of responses of plasma glucose at Dl-14:00 in 
comparison to D13-14:00 can explain why the raw means of the response of plasma glucose 
were greater but less statistically significant for average response at Dl-14:00 (Figure 2B). 
The responses of plasma insulin and glucose to multiple subcutaneous injections of 
glucagon were very similar (Figure 2). In comparison to the single-injection experiment 
(Figure 1C), concentrations of insulin were increased more significantly and for a longer 
duration in the multiple-injection experiment (P < 0.03 and 2 h for 2.5 mg and P < 0.0002 
and 3 h for 5 mg; Figure 2C). The responses of plasma insulin and glucose were similar for 
multiple in jections of 5 mg of glucagon (Figures 2B and D) because the duration of the 
insulin response increased over the 14-d injection period (2 h at Dl-14:00 and 3 h at 
D13:14:00) and the insulin response was greater at 14:00 (P < 0.01) than at 22:00 on d 1 of 
injection (P < 0.15; Figure 2D). Baseline concentrations of insulin and, to a smaller extent, 
glucose were higher at D 1-22:00 than at Dl-14:00 (Figures 2B and D). 
In contrast to the single-injection experiment (Figure ID), injections of 2.5 and 5 mg of 
glucagon every 8 h for 14 d had no overall significant effects on concentrations of plasma 
N E F A  f o r  t h e  8 - h  p o s t  i n j e c t i o n  p e r i o d  i n  t h e  m u l t i p l e - i n j e c t i o n  e x p e r i m e n t  ( P  <  0 . 8 0  a n d  P  
< 0.63; Figure 3A). Concentrations of plasma NEFA for single and multiple subcutaneous 
injections of glucagon decreased similarly (Figures ID and 3A); however, concentrations of 
plasma NEFA also decreased for the s aline-treated group in the multiple-injection 
experiment (P < 0.01). Concentrations of plasma NEFA were decreased after the injection 
of 5 mg of glucagon on Dl-14:00 (P < 0.007), when baseline concentrations of NEFA were 
highest (Figure 3B). Concentrations of plasma NEFA were decreased significantly for the 
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Figure 3. Responses of plasma NEFA and BHBA concentrations to multiple, 
subcutaneous injections of 2.5 and 5 m g of exogenous glucagon every 8 h for 14 d in 
early lactation, muciparous dairy cows (n = 3 in each treatment group) during the 8-h 
post-injection periods. A. Overall response of plasma NEFA to 2.5 mg (P < 0.80) and 5 
mg of glucagon (P < 0.63) and difference in response (P < 0.82) over the 14-d injection 
period. Concentrations were not increased significantly at either dosage. B. Response of 
plasma NEFA to 5 mg of glucagon on D 1-14:00 (P < 0.007), D 1-22:00 (P < 0.44), D7-
14:00 (P < 0.79), and D 13-14:00 (P < 0.30). Concentrations were decreased significantly 
for 4 h on 1)1-14:00 and were not affected significantly on D 1-22:00. D7-14:00, and D13-
14:00. C. Overall response of plasma BHBA to 2.5 mg (P < 0.45) and 5 mg of glucagon 
(P < 0.008) and difference in response (P < 0.05) over the 14-d injection period. 
Concentrations were decreased significantly for 15 min (2.5 mg) and 2 h (5 mg), with 
greater decreases for the first 2 h after injection after injection of 5 mg of glucagon. D. 
Response of plasma BHBA to 5 mg of glucagon on D 1-14:00 (P < 0.37), D 1-22:00 (P < 
0.91), D7-14:00 (P < 0.02), and D13-14:00 (P < 0.18). Concentrations were decreased 
significantly for 1 h on D 13-14:00 and were not affected significantly on D 1-14:00. D 1 -
22:00, and D7-14:00. 
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first 4 h (Figure 3B). Over the 14-d injection period, multiple subcutaneous injections of 5 
mg of glucagon decreased the baseline concentrations of plasma NEFA (Figure 3B). 
Multiple subcutaneous injections of 5 mg of glucagon every 8 h for 14 d decreased 
concentrations of BHBA for the 8-h post-injection period (P < 0.008) in contrast to 
injections of 2.5 mg of glucagon (P < 0.45), which resulted in significant dosage differences 
for responses of plasma BHBA (P < 0.05; Figure 3C). The overall decrease of plasma 
BHBA concentrations was greatest after the injection on D7-14:00 (P < 0.02), when 
baseline concentrations of BHBA were highest (Figure 3D). The shape of the responses of 
BHBA and NEFA to multiple subcutaneous injections of 5 mg of glucagon were similar 
(slow and persistent decrease), except that concentrations of plasma BHBA did not increase 
8 h after the injection of 5 mg of glucagon on D 1-22:00 (Figures 3B and D). 
Discussion 
The objective of the current study was to determine whether single subcutaneous 
injections of glucagon and multiple injections every 8 h for 14 d improve the carbohydrate 
status in lactating dairy cows without increasing concentrations of plasma BHBA and 
NEFA. The results document that subcutaneous injections of 5 mg of glucagon increase 
concentrations of plasma glucagon to similar peak concentrations in dairy cows as shown 
for intravenous infusions of 10 mg/d of glucagon (Figure I A; Hippen et al., 1999b; She et 
al., 1999). The response to glucagon is also similar to results in humans when subcutaneous 
and intravenous administrations of glucagon are compared (Miihlhauser et al., 1985). 
Concentrations of plasma glucagon were halved when a single dosage of 2.5 instead of 5 mg 
of glucagon was injected, indicating that the transfer of glucagon into plasma was not 
limiting at the concentrations injected. 
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The response of plasma glucose to single and multiple injections of glucagon depended 
on the dosage of glucagon injectcd, with stronger responses at the 5-mg dosage (Figures IB 
and 2A), which can be attributed to higher concentrations of plasma glucagon (Figure 1A). 
In midlactation dairy cows, the average glucose response for the 8-h post injection period 
was an increase of 14.1 mg/dl at the 5-mg dosage (see Results section), which was similar to 
14.3 mg/dl after continuous, intravenous infusions of 10 mg/d glucagon (Hippen et al., 
1999a), indicating a similar efficiency in increasing concentrations of plasma glucose. 
The response of plasma glucose to exogenous glucagon also depended on the stage of 
lactation, with greater increases in midlactation cows than in early lactation cows (Figure IB 
versus 2A), which also has been demonstrated previously with intravenous infusions of 
glucagon (Hippen et al., 1999a, b; She et al., 1999). The decreased response of plasma 
glucose to exogenous glucagon in early lactation can be explained by limited hepatic 
glycogen reserves in early lactation cows (Bobe et al., 2003a; Holtenius and Holtenius, 
1996). The increase in response of glucose to 5 mg of glucagon over the 14-d injection 
period (Figure 2B), which coincides with increased concentrations of hepatic glycogen 
(Bobe et al., 2003a), supports this hypothesis as well. Greater variability in responses of 
plasma glucose and insulin to injections of 5 mg glucagon were observed at Dl-14:00 in 
comparison to D7-14:00 and D13-14:00, which can explain why the responses at D 1-14:00 
were higher but statistically less significant than those on D7-14:00 and D13-14:00 (Figures 
2B and D). Greater variability in responses of glucose and insulin to injections of glucagon 
has been reported previously for cows in early lactation with metabolic diseases (Holtenius 
and Holtenius, 1996; Steen et al., 1997). 
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On d 1 of the multiple injection period, the responses of plasma glucose to 5 mg of 
glucagon were smaller after injections at 22:00 than at 14:00 (Figure 2B), which can be 
explained partly by feeding times, because feeding times influence diurnal variations of 
insulin concentrations (Bines et al., 1983; de Boer et al., 1985; Sutton et al., 1988). Frôhli 
and Blum (1988) saw a similar decreased response of plasma glucose when they 
intravenously infused epinephrine. Both effects can be explained by increased 
concentrations of plasma insulin after the evening feeding, which decreases hepatic 
gluconeogenesis (Donkin and Armentano, 1995). Feeding, particularly in the evening, 
increases concentrations of plasma insulin for 4-5 h (Bines et al., 1983; de Boer et al., 1985; 
Sutton et al., 1988). Such increases are shown also in the current study, where cows were 
fed at 8:00 and 18:00 and plasma insulin concentrations were higher at 22:00 than at 14:00 
(Figure ID). 
The response of plasma insulin to single and multiple injections of glucagon followed a 
trend similar to that of plasma glucose (Figures 1 and 2), which can be explained by the 
stimulatory effect of glucose on insulin secretion by the pancreas (Pipeleers et al., 1985). 
The response of plasma insulin to glucagon was statistically smaller than that of plasma 
glucose in the single-injection experiment because baseline concentrations of insulin 
decreased in the post-injection period of the single-injection experiment (10:00 to 18:00 
with feeding at 8:00 and 18:00), as can be seen also in Figure 1C. In contrast to continuous, 
intravenous infusions of glucagon (Hippen et al., 1999b; She et al., 1999), the response of 
insulin to multiple injections of 5 mg of glucagon did not decrease statistically over the 14-d 
injection period (Figure 2D), because injection of glucagon every 8 h causes fluctuations in 
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the concentration of plasma glucagon, which are similar to the pulsatile release of glucagon 
in nature (Lefèbvre et al., 1996). 
There was a concern that the responses of plasma glucose and insulin to injections of 
glucagon every 8 h would decrease over the 14-d injection period, because the cows might 
become resistant to multiple injections of glucagon, similar to development of insulin 
resistance in type II diabetes. This concern was further supported by the decrease in 
concentrations of plasma insulin during continuous intravenous infusions of glucose and 
glucagon (Holtenius and Holtenius, 1996, Hippen et al., 1999b). Responses of plasma 
glucose and insulin to 5 mg of glucagon did not decrease but rather increased over the 14-d 
injection period (Figures 2B and D), which indicates that resistance did not develop to 
multiple injections of glucagon because concentrations of glucagon fluctuate when glucagon 
is not administered continuously (Lefèbvre et al., 1996). 
Concentrations of plasma NEFA were decreased in the single-injection experiment 
(Figure ID) and after the first injection of 5 mg of glucagon in the multiple-injection 
experiment (Figure 3B), and concentrations of plasma BHBA decreased after injection of 
the 5-mg dosage in the multiple-injection experiment (Figure 3C). The decreased 
concentrations of plasma NEFA and BHBA can be explained by glucagon increasing the 
concentrations of plasma glucose and insulin. Glucagon directly increases lipolysis and 
ketogenesis (Brockman, 1976; Zupke et al., 1998), but it also indirectly decreases lipolysis 
and ketogenesis by increasing concentrations of plasma glucose and insulin, which 
decreases lipolysis and ketogenesis (Brockman, 1978). The hypothesis of an indirect effect 
of glucagon on plasma NEFA and BHBA is further supported by the shape of their response 
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to glucagon injections, because the responses of plasma NEF A and BHD A are slower and 
more persistent than those of plasma glucose and insulin. 
Another possible explanation for decreased concentrations of plasma NEF A is that 
baseline NEFA concentrations were elevated because of handling stress during 
catheterization (Reynaert et al., 1976), which was done within minutes before the first blood 
sample was taken. This explanation is unlikely, however, because concentrations of plasma 
NEFA also decreased after the first injection in the multiple-injection experiment (Figure 
3D) and in the companion study (Bobe et al., 2003a), where in both cases responses were 
compared with a control group. 
Subcutaneous injections of 5 mg of glucagon did not decrease concentrations of plasma 
NEFA in the multiple-injection experiment (Figure 3A) as 5 mg of glucagon did in the 
single-injection experiment (Figure 1D). The decrease of baseline concentrations of plasma 
NEFA (Figure 2B) and the results of a companion study (Bobe et al., 2003a) demonstrate 
overall, however, that multiple injections of 5 mg of glucagon decrease concentrations of 
plasma NEFA. Another effect of glucagon, which we also demonstrated in the companion 
study (Bobe et al., 2003a), is that responses of NEFA and BHBA were greater at elevated 
concentrations of plasma NEFA and BHBA, respectively (Figures 3B and 3D). The 
stronger decrease in concentrations of plasma NEFA and BHBA can be explained by 
glucagon indirectly preventing excess lipolysis and ketogenesis by increasing concentrations 
of plasma glucose and insulin (Brockman, 1978). 
The elevated concentrations of plasma NEFA 4-8 h after the second injection on d 1 of 
the multiple-injection experiment (Figure 3B) and 8 h after the single injection of 5 mg of 
glucagon can be explained by the short-term negative energy balance associated with the 
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long interval since the last meal (Bines et al., 1983; de Boer et al., 1985; Sutton et al., 1988). 
Another possible explanation is that the elevated concentrations of plasma NEFA are 
associated with the end of the promotion of gluconcogenesis by glucagon, similar to what 
could be observed at the end of long-term glucagon administration (Bobe et al., 2003a; 
Hippen et al., 1999a). This explanation is unlikely, however, because concentrations of 
glucose and insulin were not below baseline concentrations in either experiment (Figures 
IB, 2B and D) and because concentrations of BHBA did not increase at the end of the 14-d 
glucagon administration period (Figures 3C and D) in contrast to what is observed at the end 
of long-term glucagon administration (Bobe et al., 2003a; Hippen et al., 1999a). 
Concentrations of most plasma parameters examined were elevated significantly for 
only 4 h after subcutaneous injections of 5 m g of glucagon (Figures 1 and 2). Therefore, 
subcutaneous injections of 5 mg of glucagon every 4 h instead of every 8 h might improve 
further the carbohydrate status of lactating dairy cows. The 4-h injection interval, however, 
was not tested because a) it is less practical for on-farm usage, b) oscillating glucagon and 
glucose concentrations might be more beneficial, and c) responses of most plasma 
parameters were increased significantly for the 8-h post-injection period. 
In summary, subcutaneous injections of 5 mg and, to a smaller extent, 2.5 mg of 
glucagon in lactating dairy cows increased plasma concentrations of glucagon, glucose, and 
insulin and decreased concentrations of NEFA and BHBA. The results are indicators of an 
improved carbohydrate status. Further, there was little or no change in effectiveness of 
injections given three time daily during the 14-d injection period. Therefore, it can be 
concluded that subcutaneous injections of 5 mg of glucagon not only improve the 
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carbohydrate status of dairy cows but also may improve their metabolic and health status 
(Bobe et al., 2003b). 
Conclusions 
The current study demonstrates that both single subcutaneous injections of 5 mg of 
glucagon and multiple injections every 8 h for 14 d improve consistently the carbohydrate 
status of dairy cows and decrease concentrations of plasma NEFA and BHBA similar to 
long-term intravenous infusions of 10 mg of glucagon for 14 d, which are not practical for 
on-farm use. Therefore, subcutaneous injection of 5 mg of glucagon every 8 h for 14 d 
seem to as beneficial and are more practical than continuous, intravenous infusions of 10 mg 
of glucagon to improve the carbohydrate status and decrease elevated liver lipid 
concentrations of cows in early lactation. 
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POTENTIAL TREATMENT OF FATTY LIVER WITH 14-DAY 
SUBCUTANEOUS INJECTIONS OF GLUCAGON 
A paper submitted to the Journal of Dairy Science 
Gerd Bobe, Burim N. Ametaj, Jerry W. Young, and Donald C. Beitz 
Abstract 
Fatty liver is a major metabolic disease of dairy cows in early lactation that can be 
treated with 14-d continuous, intravenous infusions of 10 mg/d of glucagon. The objective 
was to test whether similar effects can be obtained with 14-d subcutaneous 7.5 or 15 mg 
daily dosages of glucagon beginning at d 8 postpartum. Multiparous Holstein cows (n=32) 
were grouped on the basis of their liver triacylglycerol concentration at d 8 postpartum into 
"Normal" (n=8; triacylglycerol <1% liver wet wt) and "Susceptible" (n=24; triacylglycerol 
> 1% liver wet wt) cows. "Susceptible" cows were assigned randomly to three groups and 
beginning at d 8 postpartum received 0, 2.5, or 5 mg of glucagon in 60 ml of saline by 
subcutaneous injections every 8 h for 14 d. Beginning at d 8 postpartum, "normal" cows 
received 60 ml of saline by subcutaneous injections every 8 h for 14 d. Both dosages of 
glucagon increased concentrations of plasma glucose and insulin and decreased 
concentrations of plasma NEFA. Glucagon injections of 15 mg/d decreased concentrations 
of liver triacylglycerol in cows older than 3.5 years, but not in younger muciparous cows. 
Our results document that subcutaneous injections of glucagon have the potential to 
decrease the degree of fatty liver in older dairy cows in early lactation. 
74 
Introduction 
Fatty liver (i. e., hepatic lipidosis) is recognized as a major metabolic disease that 
affects up to 50% of dairy cows in early lactation (Jorritsma et al., 2001). Fatty liver also 
increases the incidence and severity of other diseases (Rehage et al., 1996; Veenhuizen et 
al, 1991; Zerbe et al., 2000) and decreases milk production and reproductive performance 
(Veenhuizen et al., 1991; Wensing et al., 1997), thereby costing millions of dollars yearly in 
treatment, replacement, and production losses (Littledike et al., 1981). Cows with fatty liver 
are treated, similar to clinically ketotic cows, with an oral glucose precursor in mild cases 
(Studer et al., 1993) and with intravenous infusions of dextrose combined with 
glucocorticoids (Shpigel et al., 1996) or insulin (Sakai et al. 1993) in severe cases to 
improve the carbohydrate status of the cow. These compounds are effective in treating 
ketosis but have not been tested for efficacy in treating fatty liver. In a previous study in our 
group (Hippen et al., 1999), we demonstrated that continuous, intravenous glucagon 
infusions for 14 d beginning at d 21 postpartum decreased liver triacylglycerol (TAG) 
concentrations and the incidence of ketosis in dairy cows that were subjected to a protocol 
to induce fatty liver and ketosis. 
Glucagon, containing 29 amino acids, is a pancreatic hormone that improves 
carbohydrate status of cows by stimulating hepatic gluconeogenesis, glycogenosis, amino 
acid uptake, and urcagenesis (Donkin and Armentano, 1995; Flakoll et al., 1994). The 
effect of glucagon on lipid metabolism is both direct and indirect because glucagon directly 
increases lipolysis in adipose tissue but indirectly decreases lipolysis by increasing 
concentrations of plasma glucose and insulin (Brockman et al., 1975). Intravenous 
infusions of glucagon, however, are not practical for on-farm use, and fatty liver is not 
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induced artificially on farms by feed restriction and 1,3-butancdiol administration as done 
by Hippen et al. (1999). We showed in preliminary experiments that single subcutaneous 
injections of 2.5 and 5 mg of glucagon, a more practical form of glucagon administration, 
increases concentrations of plasma glucagon, glucose, and insulin for 4, 5, and 2 h, 
respectively (Bobe et al., 2003). 
Therefore, the objective of the current study was to determine whether subcutaneous 
injections of 7.5 and 15 mg/d of glucagon for 14 d starting at d 8 postpartum could be used 
to treat fatty liver. More specifically, the objective was to determine the effects of those 
daily dosages of glucagon on the composition of liver, the concentrations of key constituents 
in plasma, and the production and composition of milk. 
Materials and Methods 
Experimental Design. To increase the probability for postpartal fatty liver and 
susceptibility to ketosis, 32 muciparous Holstein cows that were housed in a straw-bedded 
free stall barn were offered daily during the final 4 wk prepartum 6 kg of cracked corn in 
addition to 12.8 kg of their typical transition dry-cow ration, which was formulated 
according to NRC recommendations and contained 3 kg of cracked corn (2001). Feeding 
additional corn for 4 wk was not as effective in inducing clinical fatty liver (liver TAG > 8% 
liver wet wt) as it was previously (Hippen et al., 1999). Probable explanations are that the 
concentration of CP in the postpartal diet was lower, current cows had lower BCS before 
com feeding (none were greater than 4.25 prepartum), and the cows had no previous history 
of ketosis in contrast to those of the previous study (Hippen et al., 1999). During the 
postpartal period, all cows were housed in a tie-stall barn and had free access to a typical 
NRC-recommended TMR for high-producing multiparous cows (Table 1). Fresh feed was 
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offered daily at 8:00 and 18:00. All cows were managed and treated in accordance with 
guidelines established by the Iowa State University Committee on Animal Care. 
Table 1. Ingredient composition of diets fed to cows during the 28-day prepartal and 43-
day postpartal periods. 
Ingredient Prepartum^ Pnstnaitnm 
(% of DM) 
Alfalfa haylage 7.9 22.6 
Corn, cracked 50.3 — 
Corn grain, ground — 30.5 
Corn gluten feed — 9.8 
Corn silage — 20.9 
Cotton seed 4.3 7.4 
Grass hay 25.2 — 
Soybean meal — 5.7 
Dry cow mineral2 1.2 — 
Lactating mineral3 — 3.1 
Limestone 0.94 — 
SoyChlorô4 8.6 — 
Transition premix5 1.5 — 
NEL (Meal/kg) 1.65 1.72 
Crude protein 15.2 16.8 
^Additional offered cracked corn is added in the ration. Total DM1 was 18.7 kg/d. 
Grass hay was also available for ad libitum intake during the prepartal period but is not 
considered for calculation of DM1. 
2Dry cow mineral obtained from Heart of Iowa (Gilbert, LA). 
^Lactating mineral obtained from Heart of Iowa (Gilbert, IA). 
4SoyChlor6 obtained from West Central Soy (Ralston, IA). 
^Transition premix obtained from Heart of Iowa (Gilbert, IA). 
At d 8 postpartum, cows were divided into two groups. Cows (n=8) with liver TAG 
concentrations of < 1 % of liver wet wt (Saline Normal) were injected subcutaneously with 
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60 ml of 0.15 M NaCl (pH 10.25) every 8 h for 14 d starting at d 8 postpartum. Cows (n=24; 
8 cows randomly assigned to each treatment) with liver TAG concentrations of > 1% of 
liver wet wt were injected subcutaneously every 8 h (6:00, 14:00, and 22:00) with 0 (Saline 
Susceptible), 2.5 (7.5 mg/d), or 5 (15 mg/d) mg of lyophilized bovine glucagon (donated by 
Eli Lilly & Co., Indianapolis, IN) dissolved in 60 ml of 0.15 M NaCl (final pH 10.25) for 14 
d starting at 14:00 of d 8 postpartum. To prevent adherence of glucagon, all glassware and 
utensils were rinsed with 1% BSA in 0.15 M NaCl (wt/vol) before use. Fresh glucagon was 
prepared every other day and stored at 4 °C until injection. For subcutaneous glucagon 
injections, the area between the 5th to 1th intercostal space, 30 to 60 cm to the right and left 
of the dorsal midline, were clipped at d 8 postpartum. Before and after injection, the 
injection site was cleaned and disinfected with 70% ethanol. The injection site was changed 
every day to avoid inflammation. We did not observe any irritation or inflammation of 
injection sites. 
Sampling and Analysis. 
Liver. Liver samples were obtained by puncture biopsies at d -4, 3, 8, 11, 15, 22, 28, 
36, and 43 postpartum. After securing the cow in a livestock handling chute, 10 ml of 
Xylocaine® (lidocaine hydochloride, 2%; Med. Tech. Inc., Elkwood, KS) was injected into 
the 10th or 11th intercostal space 30 to 40 cm to the right of the dorsal midline with a 20 
gauge needle. The injection was placed both superficially and deep into the muscle layer to 
anesthetize the incision area completely. Hair surrounding the anesthetized area was 
clipped, scrubbed with Betadine® (povidone-iodine, 7.5%; Purdue Frederick Co., Norwalk, 
CT), shaved, scrubbed again, rinsed, swabbed three times with 70% ethanol. and then 
sterilized with a tincture of iodine. The location of the liver was determined using a 
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commercially available real-time ultrasound system (Aloka Micrus 500: distributed by 
Corometrics Inc., Wallingford, CT) with a 3.5 Mhz linear transducer (Aloka model UST-
50UU-3.5). A vertical incision about 2 cm in length was made through the skin and fascia 
in the anesthetized area. A medium sized cannula (~6 mm O.D. and ~4 mm I.D.) 
surrounding a solid, retractable needle-pointed trocar was inserted through the muscle and 
peritoneum into the liver in a direction toward the left shoulder. After boring the cannula 
into the liver, a sample (1-3 g) was obtained through creating a vacuum by drawing hack the 
trocar and then flexing the tip of the cannula upward and gently pushing forward. The liver 
sample was expelled onto a clean Teri Wipe, blotted free of blood, cut into 2-cm sections, 
and placed into storage vials (catalog number 5012-0020; Nalgene Co., Rochester, NY) that 
were placed immediately in liquid nitrogen and then later stored at -80 °C until chemical 
analysis. After the biopsy, the incision was closed with two surgical staples, wiped clean, 
and treated with Nitrofurazone Dressing (Durvet Inc., Blue Springs, MO). The cow then 
was returned to her stall and monitored for labored breathing, signs of discomfort, elevated 
body temperature, and swelling at the biopsy site. One or more of those side effects 
occurred after less than 5% of all biopsies. The surgical staples were removed 7 to 10 d 
after biopsy. 
For liver lipid analysis, 250 mg of tissue were sonicated for 30 s in 10 ml of 
chloroform-mcthanol (2:1; vol/vol) in a screw-top 25x150 mm extraction tube (Model 350 
sonifier; Branson Sonic Power Corp., Danburv, CT). After samples were shaken for 12 h 
(Model 75 wrist-action shaker; Burrel Scientific, Pittsburgh, PA), 4 ml of Mil I i pore® water 
was added, and then samples were centrifuged for 20 min at 500 g (Model K centrifuge; 
International Equipment Co., Needham Hts., MA). After centrifugation, the methanol-water 
layer was aspirated and discarded. The remaining sample and chloroform were stored 
overnight at 4 °C. The next day the sample and chloroform were filtered with slight suction 
through a Buchner funnel and a 42.5-mm glass microfiber filter (Whatman International 
Ltd., Maidstone, England) into a pre weighed scintillation vial, which was followed by three 
washes with 2, 2, and 4 ml of chloroform, respectively. Extracted liver lipid samples were 
dried in the vials under forced air for 6 h at 50 °C (SC/48R sample concentrator; Brinkmann 
Instruments, Inc., Westbury, NY), and the vials then were filled with nitrogen. Samples 
were stored for 12 h at room temperature and then weighed to determine total lipids. Total 
lipid analysis was done in triplicates. For liver TAG determination, dried lipids were 
dissolved in 5 ml of 1% Triton X-100 (Fisher Scientific, Fair Lawn, NJ) in 0.15 M NaCl at 
37 °C, and liver TAG concentrations were determined for each total lipid sample in 
triplicate (TAG kit number T7532; Pointe Scientific, Lincoln Park, Ml) on a mi crop late 
spectrophotometer (SPECTRAmax PLUS. Sunnyvale, CA). 
For liver glycogen determination, 400 mg of tissue and 5 ml of 0.15 M NaCl were 
homogenized (Model 106 homogenizer; Talboys Instrument Corp., Emerson, NJ), and the 
sample then was centrifuged at 4 °C for 20 min at 2000 g. The supernatant was transferred 
to a sterile polypropylene centrifuge tube. Four samples (300 pi) of supernatant were 
transferred into microcentrifuge tubes (1.5 ml). One sample was stored at 4 °C for 
determination of free glucose. To each of the other three samples, 300 pi of 
amvloglucosidase (15 g/1, catalog number A 7255; Sigma, St. Louis, MO) and 300 |il of a 
solution, containing 50 mM pyridine acetate (catalog number P 4036; Sigma, St. Louis, 
MO) and 0.2 % sodium azide (catalog number S 8032; Sigma, St. Louis, MO), was added 
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for determination of total glucose. The mixture then was stored at 37 °C for 4 h. Glucose 
concentrations (glucose kit number 315; Sigma, St. Louis, MO) were determined in 
triplicate for each of the four samples on a microplate spectrophotometer (SPECTRAmax 
PLUS, Sunnyvale, CA). Glycogen concentrations in liver were calculated as the difference 
between total and free glucose. 
Plasma. Blood samples were collected at 7:00 from the coccygeal vein at d —4, 3, 8 
(before first injection), 9, 11, 15, 22 (after last injection), 23, 28, 36, and 43 postpartum. 
During the 14-d treatment with glucagon, we sampled one h after the morning injection, 
because this was when peak responses to glucagon injections occurred for blood 
constituents. Blood was collected into 10-ml vacutainer tubes (Beckton Dickinson and Co., 
Rutherford, NJ) containing K2-EDTA, and plasma was prepared by centrifugation within 20 
min. Plasma samples were stored at -20 °C until analyzed for concentrations of glucose 
(glucose kit number 315; Sigma, St. Louis, MO), insulin (insulin kit number TKIN; 
Diagnostic Products Corp., Los Angeles, CA), NEFA (NEFA-C kit number 994-75409; 
WAKO, Richmond, VA), BHBA (BHBA kit number 310-A; Sigma, St. Louis, MO), plasma 
urea N (PUN; kit number 640; Sigma, St. Louis, MO), and «-amino N (AMN). Plasma 
AMN concentrations were determined as based on the assay of Palmer and Peters (1969): 
200 pi of sample was filtered through a 3,000 molecular weight filter (Microcon YM-3 tube, 
Millipore, Bedford, MA) for 60 min at 14,000 g. To 10 pi of supernatant, 80 pi of 0.1 % 
Brij® 35 (catalog number 430AG-6; Sigma, St. Louis, MO) in 0.15 M NaCl, 60 pi of 0.05 
M borate buffer containing 0.1% Brij® 35 (pH 9.2), and 30 pi of 0.1% 2,4,6-trinitrobenzene 
sulfonate (catalog number P 2297; Sigma, St. Louis, MO) were added. The mixture was 
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stored for 15 min at room temperature, and then 60 pi of 1 M HC1 were added. Absorbance 
was measured at 340 nm at room temperature. Aprotinin (Boehringer-Mannheim, 
Indianapolis, IN ) was added at 500 KIU to 1 ml of plasma to be analyzed for glucagon, and 
samples were stored in glass tubes at -20 °C. Unfortunately, K^-EDTA interfered with the 
analysis of glucagon samples (glucagon kit number KGND1 ; Diagnostic Products Corp., 
Los Angeles, CA) and, therefore, results cannot be reported. 
Feed intake and Milk. Postpartal feed intake was measured twice daily until d 43. 
Body weight was measured at d -4, 3, 8, 11, 15, 22, 28, 36, and 43 postpartum. Cows were 
milked at 6:30 and 18:30, and milk production was recorded for each milking until d 43 
postpartum. Representative samples of the two milkings at d 3, 8 (before first injection), 11, 
15, 22 (before last injection), 25, 28, 36, and 43 postpartum were analyzed separately for 
protein, fat, lactose, and urea N by mid-infrared spectrophotometry (Milk-O-Scan 203, Foss 
Food Technology, Eden Prairie, MN). 
Statistical Analysis 
Data were analyzed as a completely randomized repeated measures study using the 
mixed models procedures of SAS Version 8.2 (2001). The response variable was the 
change from the concentration at d 8 postpartum (the last time point before glucagon 
injections started) to the concentration at a specific injection day. For plasma insulin and 
NEFA responses, the changes were calculated from the logarithmic concentrations of 
plasma insulin and NEFA concentrations, respectively. The fixed effects were 
concentration of the response variable at d 8 postpartum (as a linear covariate), treatment 
(Saline Normal, Saline Susceptible, 7.5 mg/d, or 15 mg/d), day of injection (1 only for 
plasma samples, 3, 7, or 14), ambient temperature (normal or > 35 °C), age of cow (< 3.5 yr 
or > 3.5 yr), treatment by day of injection interaction, treatment by ambient temperature 
interaction, and treatment by age of cow interaction. In the analysis of change in liver TAG 
and in the analysis of change in plasma insulin and NEFA concentrations, the logarithmic 
instead of the non-transformed concentration of liver TAG, plasma insulin and NEFA, 
respectively, at d 8 postpartum was used as a linear covariate. Ambient temperature was 
included in the model because hot ambient temperature decreased feed intake and caused 
metabolic changes similar to a feed restriction protocol (Vcenhuizen et al. 1991). A 
completely unrestricted variance-covariance structure was used to account for correlations 
and changes in variances for repeated measures taken on individual cows across time. The 
effects of 7.5 mg/d or 15 mg/d of glucagon were evaluated by using the ESTIMATE 
statement and comparing their estimated means with the estimated mean of the Saline 
Susceptible group. The Satterthwaite approximation for degrees of freedom with a 
Ken ward-Roger adjustment on standard errors was invoked with the KENWARDROGER 
option for degrees of freedom. The effects of elevated concentrations of liver TAG 
(Susceptible) on concentrations of response variables were evaluated by fitting the same 
statistical model as previously used for testing the effects of glucagon except that the 
response variables were the concentrations at d 8 postpartum and that day of injection and 
concentrations at d 8 postpartum as linear covariate were left out of the model. The 
estimated mean of the Saline Normal group was compared with the estimated means of the 
other three groups using the ESTIMATE statement. Means and SEMs presented in figures 
arc raw means and SEMs. Significance was declared at P < 0.05, and tendency of 
significance was declared at P < 0.10. 
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Results 
Liver. Susceptible cows had higher concentrations of TAG at d 8 postpartum than did 
normal cows (P < 0.01; Figure 1 A). Injections of 15 mg/d of glucagon injections decreased 
concentrations of TAG immediately in cows older than 3.5 yr (P < 0.02; n = 4 ), whereas 
c o n c e n t r a t i o n s  i n c r e a s e d  i n i t i a l l y  b e f o r e  t h e y  d e c r e a s e d  i n  c o w s  y o u n g e r  t h a n  3 . 5  y r  ( P  <  
0.007; n = 4; Figure IB). Susceptible cows had lower concentrations of glycogen at d 8 
postpartum than did normal cows (P < 0.04; Figure 1C). 
The glycogen response to glucagon injections was not significant (P < 0.70; Figure 1C). 
Numerically, however, glucagon injections decreased concentrations of glycogen 0.26% 
(SEM = 0.29) three days after the first injection and increased concentrations of glycogen 
0.35% (SEM = 1.65) until the end of the 14 d injection period, with both effects numerically 
slightly stronger at the 15 mg/d dosage (Figure 1C). The glycogen response to injections of 
15 mg/d of glucagon was earlier in older cows than in younger cows (Figure ID). 
Plasma. Injections of 7.5 and 15 mg/d of glucagon increased overall concentrations of 
glucose 17 and 22 mg/dl one h after injection; respectively (both P < 0.0001 ; Figure 2A). 
The increased concentrations of glucose were not only sustained over the entire period of 
glucagon injection (P < 0.004) but even increased an additional 6.7 (P < 0.007) and 4.2 
mg/dl (P < 0.08) during the injection period for injections of 7.5 and 15 mg/d of glucagon, 
respectively (Figure 2A). The increase in concentrations of glucose was greater in the 
younger cows (Figure 2B). The glucose response increased in a dose-dependent manner in 
older cows (P < 0.04; data not shown). Injections of 7.5 (P < 0.002) and 15 mg/d of 
glucagon (P < 0.0001) increased concentrations of insulin (Figure 2C). The insulin response 
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Figure 1. Effect of 7.5 and 15 mg/d of glucagon and elevated liver triacylglycerol (TAG) 
concentrations (Susceptible) on concentrations of liver TAG and glycogen overall (n = 8 
in each treatment group) and as affected by age of cows (< 3.5 yr or > 3.5 yr; n = 4 in 
e a c h  t r e a t m e n t  b y  a g e  i n t e r a c t i o n  g r o u p ) .  A .  E f f e c t  o f  S u s c e p t i b l e  ( P  <  0 . 0 1 ) ,  7 . 5  m g / d  ( P  
< 0.38), and 15 mg/d of glucagon (P < 0.56) on liver TAG (SEM = 0.08-0.79). B. Effect 
of 15 mg/d of glucagon by age interaction (P < 0.0001), effect of 15 mg/d in cows < 3.5 
yr (P< 0.007), and effect of 15 mg/d in cows > 3.5 yr (P< 0.02) on liver TAG (SEM = 
0.02-0.96). C Effect of Susceptible (P < 0.04), 7.5 mg/d (P < 0.82), and 15 mg/d of 
glucagon (P < 0.34) on liver glycogen (SEM = 0.07-0.47). D. Effect of 15 mg/d of 
glucagon by age interaction (P < 0.92), effect of 15 mg/d in cows < 3.5 yr (P < 0.48), and 
effect of 15 mg/d in cows > 3.5 yr (P < 0.49) on liver glycogen (SEM = 0.06-0.87). 
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Figure 2. Effect of 7.5 and 15 mg/d of glucagon and elevated liver triacylglycerol (TAG) 
concentrations (Susceptible) on concentrations of plasma glucose and insulin overall (n = 
8 in each treatment group) and as affected by age of cow (< 3.5 yr, > 3.5 yr; n = 4 in each 
t r e a t m e n t  b y  a g e  i n t e r a c t i o n  g r o u p ) .  A .  E f f e c t  o f  S u s c e p t i b l e  ( P  <  0 . 3 3 ) ,  7 . 5  m g / d  ( P  <  
0.0001), and 15 mg/d of glucagon (P < 0.0001) on plasma glucose (SEM = 1.0-4.2). B. 
Effect of 15 mg/d of glucagon by age interaction (f <0.16), effect of 15 mg/d in cows < 
3.5 yr (f < 0.0001), and effect of 15 mg/d in cows > 3.5 yr (f < 0.0003) on plasma 
glucose (SEM = 0.6-7.7). C. Effect of Susceptible (P < 0.17), 7.5 mg/d (P < 0.002), and 
15 mg/d of glucagon (P < 0.0001) on plasma insulin (SEM = 0.35-3.82). D. Effect of 15 
mg/d of glucagon by age interaction (P < 0.97), effect of 15 mg/d in cows < 3.5 yr (P < 
0.006), and effect of 15 mg/d in cows > 3.5 yr (P < 0.0002) on plasma insulin (SEM = 
0.16-6.20). 
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increased in a dose-dependent manner in older cows ( P  < 0.02). As for liver glycogen, the 
insulin response to 15 mg/d of glucagon injections was earlier in older cows than in younger 
cows (Figure 2D). 
Glucagon injections decreased concentrations of NEFA ( P  < 0.008; Figure 3A). 
Glucagon injections did not significantly affect concentrations of BHBA (P < 0.94; Figure 
3B). Overall, glucagon injections tended to decrease AMN concentrations (P < 0.09; Figure 
3C). Glucagon injections decreased AMN concentrations in older cows (P < 0.02) but not 
significantly in younger cows (P < 0.64; data not shown). Overall, glucagon injections did 
not affect concentrations of PUN (P < 0.97; Figure 3D). There was a glucagon by age 
interaction (P < 0.05) with increased concentrations of PUN in older cows (P < 0.07) and 
decreased concentrations of PUN in younger cows (P < 0.21 ; data not shown). 
Body Weight, DM1, Milk Production and Composition. Body weight and DM! were 
not affected by glucagon injections (P < 0.26 and P < 0.41; Figure 4A) irrespective of cow 
age or ambient temperature. Milk production (P < 0.52; Figure 4B) and concentrations and 
p r o d u c t i o n  o f  m i l k  f a t  ( P  <  0 . 9 4  a n d  P  <  0 . 4 9 ;  d a t a  n o t  s h o w n )  a n d  l a c t o s e  ( P  <  0 . 5 5  a n d  P  
< 0.85; data not shown) were not significantly affected by glucagon injection. Overall, 
glucagon injections decreased concentrations and production of milk protein (P < 0.03 and 
P < 0.05; Figure 4C) and tended to decrease concentrations of milk urea N (P < 0.10; Figure 
4D). The effects were numerically stronger at the 15-mg/d dosage. Injections of 7.5 and 15 
mg/d of glucagon decreased concentrations of protein 0.15% (SEM = 0.11; P < 0.18) and 
0.28% (SEM = 0.10; P < 0.01), respectively (Figure 4C). 
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Figure 3. Effect of 7.5 and 15 mg/d of glucagon and elevated liver triacylglycerol (TAG) 
concentrations (Susceptible) on concentrations of plasma NEFA, (3-hydroxybutyrate 
(BHBA), a-amino N (AMN), and urea N (PUN; n = 8 in each treatment group). A. Effect 
of Susceptible (P < 0.37), 7.5 mg/d (P < 0.004), and 15 mg/d of glucagon (P < 0.08) on 
plasma NEFA (SEM = 14-122). B. Effect of Susceptible (P < 0.17), 7.5 mg/d (P < 0.81), 
and 15 mg/d of glucagon (P < 0.69) on plasma BHBA (SEM = 0.8-3.3). C. Effect of 
Susceptible (P < 0.66), 7.5 mg/d (P < 0.21), and 15 mg/d of glucagon (P < 0.09) on 
plasma AMN (SEM = 1.1-3.3). D Effect of Susceptible (P < 0.63), 7.5 mg/d (P < 0.78), 
and 15 mg/d of glucagon (P < 0.70) on plasma PUN (SEM = 0.6-2.2). 
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Figure 4. Effect of 7.5 and 15 mg/d of glucagon and elevated liver triacylglycerol (TAG) 
concentrations (Susceptible) on DM1, milk production, and concentrations of milk protein 
and urea N (n = 8 in each treatment group). A. Effect of Susceptible (P < 0.84), 7.5 mg/d 
(P < 0.69), and 15 mg/d of glucagon (P < 0.28) on DM] (SEM = 0.8-3.0). B. Effect of 
Susceptible (P < 0.48), 7.5 mg/d (P < 0.48), and 15 mg/d of glucagon (P < 0.69) on milk 
production (SEM = 1.6-4.7). C. Effect of Susceptible (P < 0.75), 7.5 mg/d (P < 0.18), 
and 15 mg/d of glucagon (P < 0.01) on milk protein concentrations (SEM = 0.04-0.64). 
D. Effect of Susceptible (P < 0.20), 7.5 mg/d (P < 0.20), and 15 mg/d of glucagon (P < 
0.09) on milk urea N concentrations (SEM = 0.7-2.3). 
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Discussion 
The objective of the current study was to determine whether subcutaneous injections of 
7.5 and 15 mg/d of glucagon for 14 d starting at d 8 postpartum can be used to treat fatty 
liver similarly to continuous, intravenous infusions of 10 mg/d of glucagon (Hippen et al., 
1999). The results demonstrate that subcutaneous injections of 15 mg/d of glucagon 
decrease concentrations of liver TAG in cows older than 3.5 yr (Figures 1A and B) and, 
therefore, have the potential to treat fatty liver. These results are similar to the effect of 
continuous, intravenous infusions of 10 mg/d of glucagon in cows that were subjected to a 
fatty liver induction protocol, because 9 of the 10 cows treated with glucagon in that study 
were over 3.5 yr old (Hippen et al., 1999). We can only speculate why the younger cows 
did not respond to injections of glucagon similar to the older cows, because the metabolic 
response of the younger cows to injections of glucagon differed among the younger cows. 
A heterogeneous response to injections of glucagon among cows with clinical fatty liver has 
been observed previously by S teen et al. (1997) and can be explained partly by the 
heterogeneous etiologies that cause fatty liver (Herdt, 1988; Holtenius and Holtenius, 1996). 
Younger cows partition less gluconeogenic precursors for gluconeogenesis because they are 
still growing; however, the plasma glucose response to glucagon injections was greater in 
younger cows than it was in older cows (Figure 2B). Another probable explanation is that 
younger cows might have a different glucagon response than do older cows (Tcillet et al., 
2002), which could explain why plasma insulin and liver TAG and glycogen responses to 
glucagon injections started a few days later in younger cows than in older cows (Figures 1C, 
ID, and 2D). 
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Any ineffectiveness of injections of glucagon in younger cows is not a major problem, 
because fatty liver is a far greater problem in older cows than in younger cows (Reid 1980) 
and might be partly alleviated by dietary supplementation of gluconeogenic precursors. 
Further, increased daily dosages of glucagon could improve the beneficial responses in cows 
of all ages. In comparison to continuous, intravenous infusions of 10 mg/d of glucagon 
(Hippen et al., 1999; She et al., 1999), the metabolic responses to subcutaneous injections of 
7.5 and 15 mg/d of glucagon (Figures 1-4) were smaller, because the glucagon transfer rate 
into plasma was smaller for single subcutaneous injections of 2.5 and 5 mg of glucagon than 
for continuous, intravenous infusions of 10 mg/d of glucagon (Bobe et al., 2003; Hippen et 
al., 1999; She et al., 1999). 
Glucagon injections decreased concentrations of plasma NEFA (Figure 3A). The 
response to glucagon injections was stronger in cows with higher preinjection NEFA 
concentrations (Bobe et al., 2003), which could explain the greater effect of the lower 
glucagon dosage because those cows had higher preinjection NEFA concentrations (Figure 
3A). A possible explanation is that glucagon injections decrease lipolysis to baseline values 
for each particular stage of lactation, and, therefore, no NEFA response to glucagon can be 
detected at lower preinjection NEFA concentrations. The lower concentrations of BHBA in 
the current study (Figure 313), in comparison to those of Hippen et al. (1999), also could 
explain why we did not detect significant BHBA responses to glucagon injection as in 
another study from our group (Bobe et al., 2003). Another reason for the greater effect of 
the lower glucagon dosage could be that the higher glucagon dosage increases lipolysis in 
the absence of an insulin response to glucagon injection, which could explain the 
numerically increased concentrations of plasma BHBA and NEFA at the beginning of the 
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injection period. De Boer et al. (1986) demonstrated similar responses in ketotic and early 
lactation cows after glucagon injections. Glucagon is known to increase lipolysis and 
ketogenesis (Brockman et al., 1976; Zupke et al., 1998), but its effect is negated by 
increased insulin concentrations (Brockman et al., 1976). 
Subcutaneous injections of glucagon did not decrease DM1 or milk production (Figures 
4A and B) as did continuous infusions of glucagon in a previous study (Hippen et al., 1999; 
She et al., 1999). Therefore, subcutaneous injections of glucagon seem to be a more 
realistic choice for treatment of fatty liver than do intravenous infusions. The lack of effect 
could be related to the smaller metabolic responses to subcutaneous injections of 7.5 and 15 
mg/d of glucagon (Figures 1-4) in comparison to continuous, intravenous infusions of 10 
mg/d of glucagon (Hippen et al., 1999; She et al., 1999). Another reason could be the mode 
of administration (multiple injections vs continuous infusions), which allows the glucagon 
and insulin concentrations to regain physiological concentrations between injections (Geary, 
1996; Bobe et al., 2003). Similar to our results, Trevisi et al. (1997a,b) detected decreased 
milk production only in cows receiving continuous infusions of glucagon but not in cows 
receiving injections. The only potential disadvantage of subcutaneous injections is that 
concentrations of milk protein are decreased during the glucagon injection period (Figure 
4C; Trevisi et al., 1997b). This effect could be related to glucagon causing increased 
hepatic amino acid uptake and thereby decreasing amino acid availability of tissues without 
glucagon receptors (Dunphy et al., 1998; Flakoll et al., 1994). That hypothesis is supported 
by the results in the current study (Figures 3C and 4C). Concentrations of milk protein were 
not different between saline- and glucagon-treated cows (Figure 4C), and decreased 
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concentrations of milk proteins might be alleviated by supplementation of gluconeogenic 
precursors in the diet during glucagon injection periods (Gill et al., 1985). 
Conclusions 
The current study demonstrates that subcutaneous injections of 15 mg/d of glucagon for 
14 d beginning at d 8 postpartum decreases liver TAG concentrations in cows older than 3.5 
years; therefore, glucagon has the potential to treat fatty liver, a major metabolic disorder in 
early lactation dairy cows. In comparison to continuous, intravenous infusions, which is the 
other known treatment for fatty liver, multiple subcutaneous injections have fewer negative 
side effects (decreases in milk production and DMI) and are much more practical for on-
far m use. 
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EFFECTS OF EXOGENOUS GLUCAGON AND FATTY LIVER ON 
HEALTH STATUS AND REPRODUCTIVE PERFORMANCE OF 
LACTATING DAIRY COWS 
A paper submitted to the Journal of Dairy Science 
Gerd Bobe, Burim N. Ametaj, Jerry W. Young, and Donald C. Beitz 
Abstract 
Fatty liver, a major metabolic disease of dairy cows in early lactation, compromises 
their health status and reproductive performance, but it can be treated with 14-d continuous, 
intravenous infusions of 10 mg/d of glucagon. The objective was to test whether treatment 
of fatty liver with 14-d subcutaneous injections of glucagon at 7.5 or 15 mg/d would 
improve health status and reproductive performance in cows with elevated triacy 1 glycerol 
concentrations. Muciparous Holstein cows (n = 32) were grouped on the basis of their liver 
triacylglyceroi concentration at d 8 postpartum into "Normal" (n=8; triacylglycerol <1% 
liver wet wt) and "Susceptible" (n=24; triacylglyceroi >1% liver wet wt) cows. 
"Susceptible" cows were assigned randomly to three groups and beginning at d 8 
postpartum received 0 (same for "Normal" cows), 2.5, or 5 mg of glucagon in 60 ml 0.15 M 
NaCl by subcutaneous injections every 8 h for 14 d. Elevated liver triacylglyceroi 
concentration increased days to first ovarian activity, first estrus, and first service, number 
of luteolyses, and milk production; tended to increase the incidence of mastitis, days open, 
and number of services; and tended to decrease pregnancy rates. Injections of 15 mg/d of 
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glucagon decreased days to first ovarian activity, increased body weight loss, and tended to 
decrease mastitis after the injection period and body temperature during the injection period. 
These results document that prevention or treatment of fatty liver by subcutaneous injections 
of glucagon have the potential to improve the health status and reproductive performance of 
lactating dairy cows. 
Introduction 
Fatty liver (i. e., hepatic lipidosis), a major metabolic disease that affects up to 50% of 
dairy cows in early lactation (jorritsma et al., 2001), has detrimental effects on health status 
and reproductive performance during lactation (Kruip et al., 1996; Reid, 1983; Wensing et 
al., 1997). It also has been documented that fatty liver increases the duration and severity of 
other diseases (Hill et al., 1985; Rehage et al., 1996; Veenhuizen et al., 1991). For example, 
cows with fatty liver retained viable bacteria in the mammary gland longer than did cows 
without fatty liver (Hill et al., 1985). 
Fatty liver is associated strongly with ketosis (Crohn et al., 1987; Veenhuizen et al., 
1991), left displaced abomasum (Rehage et al., 1996), and decreased immune responses 
(Reid et al., 1984; Wensing et al., 1997; Zerbe et al., 2000). Fatty liver also increased the 
incidence of retained placenta and parturient paresis (Crohn et al., 1987) and infectious 
diseases such as lameness, mastitis, and metritis (Staufenbiel et al., 1993). Additionally, 
fatty liver has long-term negative effects by decreasing the reproductive performance 
months after an incidence of fatty liver (Kruip et al., 1996; Reid, 1983; Wensing et al., 
1997). The negative effects of fatty liver on health status and reproductive performance can 
be explained by its effect on decreasing concentrations of plasma glucose, lipids, and insulin 
and increasing concentrations of plasma NEF A and BHBA (Franklin et al., 1991; Gong et 
al.. 2002; Holtenius et al., 1989; Kandefer-Szerszen et al., 1992; Karstcn et al., 1994; Kruip 
et al., 1996; Lucy et al., 1992; Veenhuizen et al., 1991; Wensing et al., 1997). 
A previous study from our group demonstrated that the incidence and severity of fatty 
liver and ketosis can be decreased by continuous, intravenous infusions of 10 mg/d glucagon 
for 14 d (Hippen et al., 1999). In that study, however, cows were induced artificially into 
fatty liver and ketosis and the effect on reproductive and many health parameters was not 
determined. Glucagon has only minor direct effects on lymphoid organs (Koh et al., 1996) 
and no direct effects on reproductive performance, because female reproductive organs have 
no glucagon receptors (Dunphy et al., 1998). Therefore, any effects of glucagon on health 
status and reproductive performance are mediated indirectly by its effects of increasing 
concentrations of plasma glucose and insulin and thereby decreasing elevated concentrations 
of plasma NEF A and BHBA (Bobe et al., 2003a, b; Hippen et al., 1999). Preliminary 
experiments have shown that single subcutaneous injections of 2.5 and 5 mg of glucagon, a 
more practical method of glucagon administration, induces metabolic responses similar to 
those of glucagon infused intravenously (Bobe et al., 2003a, b). 
Therefore, the objective of the current study was to determine whether glucagon 
injected subcutaneously at 7.5 and 15 mg/d for 14 d starting at d 8 postpartum and elevated 
liver TAG concentrations affect health status (mammary health, vaginal discharge, body 
temperature, and urinary acetoacetate concentration) and reproductive performance (days to 
first ovarian activity, observed estrus, first service, days open, number of luteolyses and 
services, and conception rate after first service and overall) of lactating dairy cows. This 
study involved the same cows and treatments used in a companion report that focused on the 
effect of glucagon to treat fatty liver (Bobe et al., 2003b). 
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Materials and Methods 
Experimental Design. The experimental design and several of the experimental 
techniques and methods have been described in detail elsewhere (Bobe et al., 2003b). 
During their final 4 wk prepartum, 32 muciparous Hoi stein cows were housed in a free stall 
barn and offered 18.8 kg of a daily ration that primarily consisted of corn, cottonseeds, and 
grass and alfalfa hay and had 1.65 Mcal/kg NEL, 15.2% CP, 37% ADF. and 61% NDF. 
After parturition, cows were housed in a tie-stall bam and offered twice daily a TMR that 
consisted primarily of corn, alfalfa hay. cottonseed, and soybean meal and had 1.72 Mcal/kg 
NEL, 16.8% CP, 16.5% ADF, and 29% NDF (Bobe et al., 2003b). All cows were managed 
and treated in accordance with guidelines established by the Iowa State University 
Committee on Animal Care. 
At d 8 postpartum, cows were divided into two groups. Cows (n=8) with liver TAG 
concentrations of < 1% of liver wet wt (Saline Normal) were injected subcutaneously with 
60 ml of 0.15 M NaCl every 8 h (6:00,14:00, and 22:00) for 14 d starting at 14:00 of d 8 
postpartum. Cows (n=24; 8 cows randomly assigned to each treatment) with liver TAG 
concentrations of > 1% of liver wet wt were injected identically with 0 (Saline Susceptible), 
2.5 (7.5 mg/d), or 5 (15 mg/d) mg lyophilized glucagon (Bobe et al., 2003b). Table 1 
provides a general description of the cows in each treatment group prior to the injection 
period. 
Sampling and Analysis 
General Health. The incidence of metabolic and physiological disorders in the four 
treatment groups prior to the injection period is summarized in Table 2. Milk fever, defined 
by cold ears and problems or inability to stand, was treated by oral administration of one 
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tube of Cal-Gel (447 g; Jorgenson Laboratories, Inc., Loveland, CO). Retained placenta, 
defined as fetal membranes that were not expelled within 12 h after parturition, was treated 
with a single intramuscular injection of 2 ml of ECP® (2 mg estradiol cypionate/ml; 
Pharmacia & Upjohn, Kalamazoo, MI) that was followed by intravenous injections of 0.5 
Table 1. General description of the cows in each treatment group prior to the injection 
period.1 
Saline Saline 7.5 mg/d 15 mg/d SEM 
Normal Susceptible 
At calving: 
Age (yr) 3.7 4.0 4.4 3.7 0.4 
Lactation (No.) 2.5 3.0 3.3 2.6 0.4 
Calving ease2 1.00 1.50 2.00 1.25 0.27 
Day 8: 
BW (kg) 603 657 627 616 21 
BCS^ 3.40 3.69 3.42 3.45 0.15 
DMI (kg/d) 17.8 18.6 18.3 16.7 1.7 
Mllk(kg/d) 29.6 36.1 32.7 31.6 2.7 
Cows (n=8) with a liver triacylglyceroi (TAG) concentration of < I % of liver wet wt 
(Saline Normal) were injected subcutaneously with 60 ml of 0.15 M NaCl (pH 10.25) every 
8 h for 14 d starting at d 8 postpartum. Cows (n=24; 8 cows randomly assigned to each 
treatment) with a liver TAG concentration of > 1% of liver wet wt were injected 
subcutaneously every 8 h with 0 (Saline Susceptible), 2.5 (7.5 mg/d). or 5 (15 mg/d) mg of 
glucagon dissolved in 60 ml of 0.15 M NaCl (final pH 10.25) for 14 d starting at d 8 
postpartum. 
"Calving ease: 1 = no problem, 2 = slight problem, 3 = needed assistance, 4 = considerable 
force, and 5 = extreme difficulty. 
3Body condition score: 1 = extremely thin to 5 = extremely obese (Edmonson et al., 1989). 
102 
ml of oxytocin (20 LISP posterior pituitary units/ml; Vet Tek, Blue Springs, MO) twice a 
day for three days or until the placenta was expelled. If the placenta was not expelled by d 2 
postpartum, the cow was injected intramuscularly with 5 ml of Lutalyse® (50 mg/ml PGF2u; 
Pharmacia & Upjohn, Kalamazoo, MI), and a veterinarian removed the retained placenta 
manually if possible. 
Table 2. Incidence of metabolic and physiological disorders in each treatment group prior 
to the injection period.1 
Disorder Saline Saline 7.5 mg/d 15 mg/d 
Normal Susceptible 
Number of cows (out of 8 cows per treatment) 
Milk fever 1 0 2 1 
Retained placenta 1 2 3 1 
Mastitis 4 3 4 6 
Diarrhea 4 3 2 5 
Metritis 2 2 4 2 
Body temperature 5 6 6 5 
> 39.5 °C 
Urinary 0 0 2 3 
acetoacetate > 40 
mg/dl 
None 2 2 0 1 
'See footnote 1 of Table 1. 
Cows were monitored twice daily for mastitis, defined as flakes in the milk. Mastitis 
was treated with intravenous injections of 0.5 ml of oxytocin twice a day for three 
consecutive days or until it subsided. In severe cases, an antibiotic that was prescribed by a 
veterinarian was injected into the teat canal twice a day for three consecutive days. 
Infections, such as winter dysentery, pneumonia, and inflammations, were verified by a 
veterinarian and treated by intramuscular injections of 20 ml of Excenel RTE (50 mg/ml; 
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Pharmacia & Upjohn, Kalamazoo, MI) once a day for three consecutive days. Stool 
consistency was monitored twice daily. Diarrhea was treated by oral administration of three 
tablets of Carmilax® Bolets® (27 g Mg(OH)2/tablet; Pfizer Animal Health, Exton, PA). 
Metritis, defined by vaginal discharge that had foul odor, thin and watery consistency, 
and reddish-brown consistency, was treated with uterine infusions of 1 L of 0.02% iodine in 
0.15 M NaCl. Vaginal discharge was monitored twice daily and classified into four 
categories on the basis of odor, consistency, and appearance of discharge. Puslike discharge 
had foul odor, purulent or watery consistency, and whitish-yellow or reddish-brown 
appearance. White discharge had normal odor, purulent consistency, and whitish-yellow 
appearance. Bloody discharge had normal odor, thick consistency, and reddish-clear 
appearance. Clear discharge had normal odor, thick consistency, and clear appearance. 
Body temperature and urinary acetoacetate concentrations of cows were measured daily 
at 9:00. Body temperatures above 40 °C were treated by oral administration of four tablets 
of Aspirin Bolus® (15.6 g acetylsalicylic acid/tablet; Durvet, Inc.; Blue Springs. MO). 
Clinical ketosis, defined as urinary acetoacetate concentrations above 40 mg/dl, decreased 
DMI and milk production by more than 30%, and behavioral changes indicative of ketosis, 
was not observed. 
Reproduction. The reproductive tract was palpated reel all y by a veterinarian every 2 
wk beginning at 30 d postpartum. Ovarian activity was defined as the presence of at least 
one ovarian corpus luteum or follicle. Estrus behavior (defined as cows allowing mounting, 
mounting other cows, and having mucus discharge) was monitored for 1 h twice daily. 
Some cows only showed mucus discharge and a red swollen vulva during estrus. Cows that 
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were at least 42 DIM were confirmed open, and those that had at least one corpus luteum 
were injected subcutaneously with 5 ml of Lutalyse®. Cows that were at least 45 DIM were 
inseminated 12 h after they allowed mounting. One cow in the Saline Normal group and 
one cow in the 15 mg/d Glucagon group each had one luteal cyst (fluid-filled structures > 
2.5 cm) and were treated with intramuscular injections of 5 ml of Lutalyse® and 2 ml of 
Cystorelin® (50 fxg/ml GnRH; Sanofi Animal Health, Overland Park, ICS).. Cows whose 
previous insemination passed at least 35 d without any estrus were palpated for pregnancy. 
One cow in the 7.5 mg/d Glucagon group and one cows in the Saline Susceptible group 
aborted after being confirmed pregnant and did not conceive thereafter. 
Body Weight, BCS, Milk Production and Composition. Body weight was measured 
at d 8 and 43 postpartum. Every 2 wlc, BCS was evaluated independently by three trained 
evaluators on a five-point scale [1 = extremely thin to 5 = extremely obese (Edmonson et al., 
1989)]. Cows were milked at 6:30 and 18:30. Milk production was recorded for 1 d once 
monthly until the cow was either dried off or culled. A representative sample of the two 
milkings for that day was analyzed for protein, fat, and somatic cell count by mid-infrared 
spectrophotometry (Milk-O-Scan 203; Foss Food Technology, Eden Prairie, MN). 
Statistical Analysis. 
The response variables were analyzed as a completely randomized design by using the 
GENMOD, LIFEREG, or MIXED procedure of SAS Version 8.2 (2001). The fixed effects 
for all response variables were treatment (Saline Normal, Saline Susceptible, 7.5 mg/d, or 
15 mg/d), ambient temperature (normal or > 35 °C), and age of coxv (< 3.5 yr or > 3.5 yr). 
The effects of elevated liver TAG concentration (Susceptible) and injections of 7.5 and 15 
mg/d of glucagon were evaluated by comparing the estimated mean of the Saline 
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Susceptible group with the estimated mean of the Saline Normal, the 7.5 mg/d, and the 15 
mg/d group, respectively. To test those effects, the ESTIMATE statement in the GEN MOD 
and MIXED procedure and the SOLUTION statement in the LIFEREG procedure were 
used. 
Response variables that were analyzed by using the GENMOD procedure were 
assumed to be Poisson distributed and for response variables that contained zeros either 0.01 
or 0.1 was added to the count. The response variables were (A) number of d per wk with 
mastitis during or after the glucagon injection period, (B) last day with puslike, white, or 
bloody discharge, first day with clear discharge, (C) number of d per wk with a body 
temperature greater than 39.5 °C during or after the glucagon injection period, (D) number 
of d per wk with urinary acetoacetate concentrations greater than 40 mg/dl during or after 
the glucagon injection period, and (E) number of luteolyses and services per cow. For (A), 
the linear covariate was the number of days with mastitis before the injection period, for (B) 
the number of days with retained placenta, for (C) the number of days with body 
temperature greater than 39.5 °C postpartum before the injection period, and for (D) the 
number of days with urinary acetoacetate concentrations greater than 15 mg/dl. 
Response variables, including days to first ovarian activity, first observed estrus, and first 
service, and days open were analyzed by using the Weibull distribution in the LIFEREG 
procedure. Data for reproductive responses of cows that did not conceive were censored 
statistically for the day a decision was made not to inseminate the cow again. Treatment 
effects on the number of cows per treatment with mastitis during lactation and the 
pregnancy rates after the first service and overall were analyzed using Fisher's Exact test. 
In this analysis, incidence rates for Saline Normal, 7.5 mg/d, and 15 mg/d groups were 
compared against the Saline Susceptible group. By using the MIXED procedure, responses 
for body weight and BCS at d 43 postpartum, changes in body weight and body condition 
scores from d 8 to 43 postpartum, and 305-d mature equivalent responses for milk 
production and composition were analyzed by using a model with only fixed effects. The 
linear covariate was the response variable at d 8 postpartum. 
One cow in each of the Saline Normal, 7.5, and 15 mg/d groups was omitted for 
analysis of the 305-d mature equi valent production because they were culled with less than 
120 DIM. One cow of the 7.5 and 15 mg/d group each (n = 2) were omitted for analysis of 
pregnancy rates, first breeding, and days open because we decided soon after parturition to 
not inseminate those cows again. Means and SEMs presented in figures and tables are raw 
means and SEMs. Significance was declared at P < 0.05, and tendency of significance was 
declared at P < 0.10. 
Results 
General Health. Cows with elevated liver TAG concentration (Figure 1 A) tended to 
have more days of mastitis during (P < 0.06) and after (P < 0.04) the injection period and 
tended to have a higher incidence of mastitis throughout the lactation (P < 0.06). 
Combining data from both dosages showed that glucagon injections decreased the incidence 
of mastitis throughout the lactation (P < 0.007) and tended to decrease the incidence of 
mastitis after the injection period (P < 0.09: P-values for overall glucagon effects and 
dosage differences are shown only in Results section). The effect of glucagon (15 versus 
7.5 mg/d) on the incidence of mastitis during (P < 0.13 versus P < 0.63) and after (P < 0.06 
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F i g u r e  1 .  E f f e c t  o f  e l e v a t e d  l i v e r  t r i a c y l g l y c e r o i  ( T A G )  c o n c e n t r a t i o n s  ( S u s c e p t i b l e )  a n d  
7 . 5  a n d  1 5  m g / d  o f  g l u c a g o n  o n  h e a l t h  s t a t u s  i n  l a c t a t i n g  d a i r y  c o w s  ( n  =  8  i n  e a c h  
t r e a t m e n t  g r o u p ) .  A .  N u m b e r  o f  d a y s  p e r  w e e k  w i t h  m a s t i t i s  b e f o r e  g l u c a g o n  t r e a t m e n t  
( D I M :  1 - 8 ) ,  d u r i n g  g l u c a g o n  t r e a t m e n t  ( D I M :  9 - 2 2 )  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 0 6 ) ,  
7 . 5  m g / d  ( P  <  0 . 6 3 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 1 3 ) ,  a n d  a f t e r  g l u c a g o n  t r e a t m e n t  
( D I M  :  2 3 - 4 3 )  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 0 4 ) ,  7 . 5  m g / d  ( P  <  0 . 2 3 ) ,  a n d  1 5  m g / d  o f  
g l u c a g o n  ( P  <  0 . 0 6 ) .  N u m b e r  o f  c o w s  p e r  t r e a t m e n t  t h a t  h a d  m a s t i t i s  d u r i n g  l a c t a t i o n  a s  
a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 0 6 ) ,  7 . 5  m g / d  ( P  <  0 . 0 2 ) ,  a n d  1 5  m g / d  g l u c a g o n  ( P  <  0 . 0 6 ) .  
B  L a s t  d a y  p o s t p a r t u m  w i t h  p u s l i k e  d i s c h a r g e  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 1 7 ) ,  7 . 5  
m g / d  ( P  <  0 . 7 6 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 9  9 ) .  L a s t  d a y  p o s t p a r t u m  w i t h  w h i t e  
d i s c h a r g e  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 4 3 ) ,  7 . 5  m g / d  ( P  <  0 . 8  5 ) ,  a n d  1 5  m g / d  o f  
g l u c a g o n  ( P  <  0 . 4 3 ) .  L a s t  d a y  p o s t p a r t u m  w i t h  b l o o d y  d i s c h a r g e  a s  a f f e c t e d  b y  
S u s c e p t i b l e  ( P  <  0 . 4 4 ) ,  7 . 5  m g / d  ( P  <  0 . 5  8 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 5 1 ) .  F i r s t  
d a y  p o s t p a r t u m  w i t h  c l e a r  d i s c h a r g e  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 4  7 ) ,  7 . 5  m g / d  ( P  <  
0 . 4 4 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 6 4 ) .  C .  N u m b e r  o f  d a y s  w i t h  b o d y  t e m p e r a t u r e s  
g r e a t e r  t h a n  3  9 . 5  ° C  b e f o r e  g l u c a g o n  t r e a t m e n t  ( D I M  :  1 - 8 ) ,  d u r i n g  g l u c a g o n  t r e a t m e n t  
( D I M :  9 - 2 2 )  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 2 3 ) ,  7 . 5  m g / d  ( P  <  0 . 3 2 ) ,  a n d  1 5  m g / d  o f  
g l u c a g o n  ( P  <  0 . 0 8 ) ,  a n d  a f t e r  g l u c a g o n  t r e a t m e n t  ( D I M  :  2  3 - 4 3 )  a s  a f f e c t e d  b y  
Susceptible (P < 0.93), 7.5 mg/d (P S 0.0 8), and 15 mg/d of glucagon (P < 0.30). D. 
N u m b e r  o f  d a y s  p e r  w e e k  w i t h  u r i n a r y  a c e t o a c e t a t e  c o n c e n t r a t i o n s  g r e a t e r  t h a n  4 0  m g / d l  
b e f o r e  g l u c a g o n  t r e a t m e n t  ( D I M :  1 - 8 ) ,  d u r i n g  g l u c a g o n  t r e a t m e n t  ( D I M :  9 - 2 2 )  a s  a f f e c t e d  
b y  S u s c e p t i b l e  ( P  <  0 . 7 3 ) ,  7 . 5  m g / d  ( P  <  0 . 2 7 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 1 3 ) ,  a n d  
a f t e r  g l u c a g o n  t r e a t m e n t  ( D  I M  :  2  3 - 4 3 )  a s  a f f e c t e d  b y  S u s c e p t i b l e  ( P  <  0 . 1 1 ) ,  7 . 5  m g / d  ( P  
<  0 . 0 9 ) ,  a n d  1 5  m g / d  o f  g l u c a g o n  ( P  <  0 . 4 9 ) .  
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versus P < 0.23) the glucagon injection period was stronger with the 15-mg/d dosage 
(Figure 1A). 
Elevated liver TAG concentration did not affect the number of days with puslike (P < 
0.17), white (P < 0.43), or bloody vaginal discharge (P < 0.44) or days until clear discharge 
was secreted (P < 0.47; Figure IB). Overall, injections of glucagon did not affect the 
duration of puslike (P < 0.98), white (P < 0.57), or bloody vaginal discharge (P < 0.98) or 
the days until clear discharge was secreted (P < 0.85). However, days until bloody 
discharge ended (P < 0.08) and days until clear discharge was secreted (P < 0.07) tended to 
be fewer at 15-mg/d in comparison to the 7.5-mg/d dosage (Figure IB). 
Neither elevated liver TAG concentration (P < 0.23 during and P < 0.93 after the 
glucagon injection period; Figure 1C) nor glucagon injections overall (P < 0.14 during and 
P < 0.17 after the glucagon injection period) affected the incidence of elevated body 
temperature. However, injections of 15 mg/d of glucagon tended to decrease the incidence 
of elevated body temperature during the glucagon injection period (P < 0.08), and injections 
of 7.5 mg/d of glucagon tended to increase the incidence of elevated body temperature after 
the glucagon injection period (P < 0.08; Figure 1C). 
Neither elevated liver TAG concentrations (P < 0.73 during and P < 0.11 after the 
glucagon injection period; Figure ID) nor glucagon injections affected the incidence of 
urinary acetoacetate concentrations greater than 40 mg/dl during the glucagon injection 
period (P < 0.23). Injections of 7.5 mg/d but not of 15 mg/d of glucagon tended to increase 
the incidence of urinary acetoacetate concentrations greater than 40 mg/dl after the glucagon 
injection period (P < 0.09 versus P < 0.49; Figure ID). Injections of 15 mg/d of glucagon 
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increased urinary acetoacetate concentrations greater than 15 mg/dl during ( P  <  0.05) but 
not after (P < 0.80) the glucagon injection period (data not shown). 
Reproduction. Elevated liver TAG concentrations (Figure 2) increased days to first 
ovarian activity (P < 0.0004), first observed estrus (P < 0.05). first service (P < 0.007), and 
the number of luteolyses (P < 0.04). Elevated liver TAG concentrations tended to increase 
days open (P< 0.10) and number of services (P < 0.10) and tended to decrease the overall 
pregnancy rate (P < 0.10; Figure 2). Combining both dosages, subcutaneous injections of 
glucagon overall decreased days to first ovarian activity (P < 0.003; P-value not in Figure 
2A). The days to first observed estrus were fewer (P < 0.01) for cows injected with 15 in 
comparison to 7.5 mg/d. There was a tendency for a dosage effect of glucagon for number 
of luteolyses (P < 0.10) with a lower number for cows injected with the 7.5-mg/d dosage (P 
< 0.10 versus P < 0.78; Figure 2C). 
Body Weight, DMI, and Milk Production and Composition. Elevated liver TAG 
concentrations (Table 3) did not affect BW (P < 0.78), BW change (P < 0.74), BCS (P < 
0.82), or BCS change (P < 0.53), but they increased milk production throughout the 
lactation (P < 0.05). Injections of 15 mg/d of glucagon had no effect on BCS (P < 0.22), 
BCS change (P < 0.62), or milk production throughout the lactation (P < 0.53; Table 3). 
Injections of 15 mg/d of glucagon decreased BW (P < 0.04) and BW change between d 8 
and 43 postpartum (P < 0.02; Table 3) but not throughout the glucagon injection period (P < 
0.13; data not shown). Injections of 7.5 mg/d glucagon tended to increase milk fat 
concentrations (P < 0.07), but had no effect on other response variables (Table 3). 
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Figure 2. Effect of elevated liver triacylglyceroi (TAG) concentrations (Susceptible) and 
7.5 and 15 mg/d glucagon (7.5 and 15 mg/d) on reproductive performance in lactating 
dairy cows (n = 8 in each treatment group). A. First ovarian activity as affected by 
Susceptible (P < 0.0004), 7.5 mg/d (P < 0.0006), and 15 mg/d of glucagon (P < 0.0027) 
and first observed estrus as affected by Susceptible (P < 0.05), 7.5 mg/d (P < 0.79), and 
15 mg/d of glucagon (P < 0.29). B. First service as affected by Susceptible (P < 0.007), 
7.5 mg/d (P < 0.19), and 15 mg/d of glucagon (P < 0.42) and days open as affected by 
Susceptible (P < 0.10), 7.5 mg/d (P < 0.25), and 15 mg/d of glucagon (P < 0.94). C. 
Number of luteolyses per cow as affected by Susceptible (P < 0.04), 7.5 mg/d (P < 0.10), 
and 15 mg/d of glucagon (P < 0.78) and number of services per cows as affected by 
Susceptible (P < 0.10), 7.5 mg/d {P < 0.58), and 15 mg/d of glucagon (P < 0.97). D. 
Pregnancy rate of first service as affected by Susceptible (P < 0.24), 7.5 mg/d (P < 0.39), 
and 15 mg/d of glucagon (P < 0.39) and overall pregnancy rate as affected by Susceptible 
(P < 0.10), 7.5 mg/d (P < 0.39), and 15 mg/d of glucagon (P < 0.29). 
I l l  
Table 3. Effect of elevated liver triacylglyceroi (Susceptible) concentrations and 7.5 and 15 
mg/d of glucagon on BW, BCS, and milk production and composition/ 
Treatments Type m SS ? > F 
Saline Saline 7.5 mg/d 15 mg/d Cl% C2^ C3* 
Normal Susceptible 
BW (kg) at 43 DIM: 
Mean 592 629 603 568 0.04 0.79 0.78 
Decrease (d8-d43) 11 28 24 48 0.02 0.75 0.74 
BCS^ at 43 DIM: 
Mean 3.09 3.32 3.01 2.85 0.22 0.92 0.82 
Decrease (d8-d43) 0.30 0 36 0.40 0.59 0.62 0.49 0.53 
Production 
(305-dME^): 
Milk (kg) 11,086 12,973 12,189 12,895 0.91 0.25 0.05 
Milk fat (kg) 416 459 477 472 0.49 0.47 0.60 
Milk fat (%) 3.72 3.56 3.93 3.66 0.52 0.07 0.32 
Milk protein (kg) 335 376 357 381 0.68 0.37 0.17 
Milk protein (%) 3.03 2.91 2.93 2.96 0.68 0.90 0.80 
'See footnote 1 of Table 1. 
2C1 : contrast between 15 mg/d and Saline Susceptible (effect of 15 mg/d glucagon). 
3C2: contrast between 7.5 mg/d and Saline Susceptible (effect of 7.5 mg/d glucagon). 
4C3: contrast between Saline Normal and Saline Susceptible (effect of susceptibility). 
5Body condition score: 1 = extremely thin to 5 = extremely obese (Edmonson et al., 1989). 
6305-d mature equivalent production. 
DISCUSSION 
The objective of the current study was to determine whether subcutaneous injections of 
glucagon at 7.5 and 15 mg/d for 14 d starting at d 8 postpartum has any beneficial effects on 
the health status and reproductive performance of lactating dairy cows with elevated liver 
TAG concentrations. The results demonstrate that elevated liver TAG concentrations 
increase the incidence of mastitis and that those negative effects can be decreased by 
subcutaneous injections of 15 mg/d of glucagon (Figure 1 A). These results are supported by 
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those of Hill et al. (1985), who reported that cows with fatty liver retained viable bacteria in 
the mammary gland longer than did cows without fatty liver, which is associated with 
decreased immune responses in cows with fatty liver (Reid et al., 1984; Wensing et al., 
1997; Zcrbe et al., 2000). We hypothesize that the ability of glucagon to decrease 
susceptibility of the mammary gland to infections is related to the ability of glucagon to 
increase concentrations of plasma glucose and insulin and to decrease elevated 
concentrations of plasma NEF A and BHBA (Bobe et al., 2003a, b; Hippen et al. 1999). 
High concentrations of plasma NEFA and BHBA have been reported to decrease the 
immune response (Franklin et al., 1991; Kandefer-Szerszen et al., 1992; Karsten et al., 
1994). Direct effects of glucagon on the mammary gland and the immune system are 
unlikely, because the mammary gland has no glucagon receptors (Dunphy et al., 1998) and 
the direct effect of glucagon on the immune system is reported to be minor (Koh et al., 
1996). 
Beneficial effects of 15 mg/d of glucagon and low concentrations of liver TAG in the 
early postpartal period not only decreased the incidence of mastitis during early lactation but 
throughout the entire lactation (Figure 1A). These results indicate that prevention and 
treatment of fatty liver by subcutaneous injections of 15 mg/d of glucagon in the peri parlai 
period, during which dairy cows are more susceptible to infections (Lee and Kchrli, 1998; 
Zerbe et al., 1998), has beneficial, long-term effects on mammary health and is a potential 
tool to improve mammary health throughout lactation. 
The incidence and severity of other infectious disorders were not affected significantly 
by elevated concentrations of liver TAG or injections of glucagon (Figures IB, 1C). The 
absence of an effect of elevated concentrations of liver TAG on vaginal discharge and body 
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temperature can be explained by the following facts. The incidence and severity of those 
disorders is linearly associated with the degree of lipid infiltration of liver (Rehage et al., 
1996; Stauffenbiel et al., 1993), and cows in the current study had only mild to moderate 
hepatic lipidosis (1-4% liver TAG/liver wet wt; Bobe et al., 2003b). There was a tendency, 
however, that injections of 15 mg/d of glucagon decreased the incidence of elevated body 
temperature during the glucagon injection period (Figure 1C) and that injections of 15 mg/d 
improved uterine health faster than did 7.5 mg/d glucagon (Figure I B). Our results indicate 
that injections of 15 mg/d of glucagon in the peripartal period should be investigated further 
as a supplemental tool to traditional treatments to decrease the incidence and severity of 
infections diseases in the peripartal period. 
The incidence of urinary acetoacetate concentrations above 40 mg/dl, which is one of 
the indicators of subclinical ketosis, was not affected by elevated concentrations of liver 
TAG or by injections of 15 mg/d of glucagon (Figure ID). The absence of an effect of 
elevated concentrations of liver TAG on concentrations of urinary acetoacetate can be 
explained by the fact that cows in the current study had only mild to moderate fatty liver and 
concentrations of plasma BHBA were not increased (Bobe et al., 2003b). Therefore, we 
were unable to test whether subcutaneous in jections of 7.5 and 15 mg/d of glucagon can 
decrease the incidence of clinical ketosis after glucagon injections as did continuous, 
intravenous infusions of 10 mg/d of glucagon (Hippen et al. 1999). Injections of 15 mg/d of 
glucagon increased concentrations of urinary acetoacetate above 15 mg/dl but not above 40 
mg/dl during the injection period (Figure ID), but did not increase concentrations of plasma 
BHBA (Bobe et al., 2003a, b). These results indicate that glucagon can cause a moderate 
increase in ketogenesis (Zupke et al., 1998) without reaching urinay ketone concentrations 
indicative of subclinical ketosis, which could be potentially harmful to the health of cows 
(Franklin et al., 1991 ; Kandefer-Szerszen et al., 1992). 
Clinical fatty liver has been shown to decrease reproductive performance (Kruip et al., 
1996; Reid, 1983; Wensing et al., 1997). The current study demonstrates that even mild to 
moderate hepatic lipidosis ( 1 -4% liver TAG/ liver wet wt; Bobe et al., 2003b) also can 
compromise reproductive performance (Figure 2). We hypothesize that the ability of fatty 
liver to decrease reproductive performance is associated with decreased concentrations of 
insulin and increased concentrations of plasma NEF A (Bobe et al., 2003a, b; Hippen et al. 
1999). Both factors have been shown to decrease follicular growth and oocyte survival 
(Gong et al., 2002; Kruip et al., 1996; Lucy et al., 1992; Wensing et al., 1997) and can 
decrease oocyte survival until 120 DIM (Kruip et al., 1996; Wensing et al., 1997). 
Another possible way that fatty liver can decrease reproductive performance is that fatty 
liver is associated with decreased feed intake, increased negative energy balance, and 
increased loss of body weight (Jorritsma et al., 2001; Kruip et al., 1996; Veenhuizen et al., 
1991). The decreased feed intake and increased negative energy balance decreases the 
availability of glucose, amino acids, and lipids (Hippen et al., 1999; Holtenius, 1989; 
Veenhuizen et al., 1991) as precursors for ovarian activity and uterine involution that begins 
in the early postpartal period (Asian et al., 2002; Gong et al., 2002). Increased negative 
energy balance also is associated with higher milk production, which can explain why cows 
with moderate hepatic lipidosis have greater milk production than cows with no hepatic 
lipidosis (Gerloff et al., 1986; Staufenbiel et al., 1993). Similar results are shown in our 
study (Table 3). 
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Subcutaneous injections of glucagon decreased the number of days until the first 
observed ovarian activity (Figure 2A) and numerically decreased most of the other 
reproductive parameters (Figure 2). We hypothesize that glucagon decreases the negative 
effects of fatty liver on reproductive performance by increasing glucose and insulin 
concentrations and decreasing elevated concentrations of plasma NEFA and BHBA during 
the glucagon injection period (Bobe et al., 2003a, b; Hippen et al., 1999). The reasons are 
described in the previous two paragraphs. A direct effect of glucagon on reproductive 
performance is unlikely, because female reproductive organs do not have glucagon receptors 
(Dunphy et al., 1998). The lack of a stronger positive effect of glucagon on reproductive 
parameters, other than ovarian activity, might be related to glucagon increasing body weight 
loss after the glucagon injection period (Table 3 and Results section). 
In summary, our results demonstrate that prevention of fatty liver likely would improve 
reproductive performance of lactating dairy cows in typical on-farm situations. The 
decreased number of days to first ovarian activity and the numerically lower values for other 
reproductive parameters (Figure 2) in cows treated with glucagon suggest strongly that 
subcutaneous injections of glucagon in the peripartal period could be used as a management 
tool to improve reproductive performance of lactating dairy cows. Increased daily dosages 
of glucagon and dietary supplementation with gluconeogenic precursors likely would further 
improve the beneficial responses of glucagon on reproductive performance. A large-scale 
field study would help to better understand the usefulness of glucagon on health status and 
reproductive performance. 
116 
Conclusions 
The current study demonstrates that elevated liver TAG concentrations, even at 
concentrations of 1-4% liver wet wt, have detrimental effects on mammary health and 
reproductive performance. Administration of at least 15 mg/d of glucagon for 14 d 
beginning at d 8 postpartum, or even earlier, seems likely to alleviate many negative side 
effects of elevated liver TAG concentrations on mammary health and to improve 
reproductive performance. Therefore, prevention and treatment of fatty liver by 
subcutaneous injections of glucagon has excellent potential to improve the overall 
performance and profitability of lactating dairy cows. 
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GENERAL CONCLUSIONS 
General Discussion 
The objective of the current study was to test whether the more practical multiple 
subcutaneous injections of 7.5 and 15 mg/d of glucagon for 14 d causes metabolic responses 
similar to continuous, intravenous infusions of 10 mg/d of glucagon, and therefore, could be 
an effective treatment for fatty liver. The results of the three papers document that 
subcutaneous injections of 5 mg of glucagon every 8 h for 14 d have strong potential to treat 
fatty liver, as evidenced by the decrease in concentrations of liver triacylglycerols (TAG) in 
older cows. Decreased concentrations of liver TAG can be attributed to improvement of the 
metabolic status by glucagon throughout the injection period. Injections of 15 mg/d of 
glucagon consistently increased concentrations of plasma glucose and insulin during the 14-
d injection period and decreased concentrations of plasma NEFA and BHBA. The 
improvement of metabolic status also can explain why cows treated with glucagon have a 
lower incidence of mastitis and decreased days to first ovarian activity, which are both 
negatively affected by elevated concentrations of liver TAG. 
The beneficial effects of subcutaneous injections of glucagon in periparturient cows 
with fatty liver were expected, based on what is known about the physiological effects of 
glucagon. Fatty liver and glucagon have their primary effects on liver. Glucagon 
counteracts the primary detrimental effects of fatty liver by reversing the decrease in hepatic 
gluconeogenesis, ketogenesis, (3-oxidation, and ureagenesis and the increase in synthesis of 
hepatic TAG. On the basis of previous studies, other hormones are less effective in 
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reversing the detrimental effects of fatty liver and also have some detrimental side effects. 
Therefore, glucagon seems to be superior to other hormones for treatment and/or prevention 
of fatty liver. 
One challenge of the current study is that only the cows more than 3.5 yr old responded 
immediately to injections of 15 mg/d of glucagon with increased concentrations of plasma 
insulin and decreased concentrations of liver TAG. In cows that were less than 3.5 yr old, it 
took 3-7 d longer until concentrations of liver TAG began to decrease, which can be 
explained by the smaller increase in concentrations of plasma insulin in response to 
glucagon during the first days of injections of glucagon and the lower concentrations of liver 
glycogen before treatment. Administration of higher dosages of glucagon and/or feeding of 
gluconeogenic precursors might improve the beneficial effects of glucagon in treatment of 
fatty liver. 
Recommendations for Future Research 
The current study answered several questions but raised even more questions. One 
question is what are the physiological reasons why older cows have different metabolic 
responses than do younger cows to injections of glucagon. More generally and on the 
cellular level, what determines the metabolic response of dairy cows to glucagon. A study 
that also would investigate the effects of glucagon on adipose tissue and the pancreas should 
help to better understand differences in metabolic responses. Combining glucagon 
treatments with oral administration of glucose precursors, as will be done in a follow-up 
study, may alleviate the lack of response to glucagon in some of the treated cows. A 
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question for future studies will remain: which is the best glucose precursor for combined 
treatment with glucagon — a precursor that has a high or low gluconeogenic capacity in the 
presence of glucagon. 
Multiple subcutaneous injections of glucagon are considerably more practical for on-
farm use than are continuous, intravenous infusions. The ultimate goal, however, must be to 
develop a slow-release formulation of glucagon that is similar to slow-release insulin or 
growth hormone that has to be administered only once every 14 d. A challenge for the 
development of a slow-release formulation of glucagon is that multiple injections of 
glucagon might exhibit more favorable metabolic responses than do continuous infusions. 
One possible advantage for a slow-release formulation is that the response to exogenous 
glucagon increases during the treatment period. 
A challenge in the current study, as well as in previous studies, was to consistently 
induce fatty liver without aggressive intervention by starvation and/or morbid obesity. A 
proposed gene microarray study will give some insight into cellular aspects of the etiology 
of fatty liver. It would be interesting to know which molecular reactions at the cellular level 
will tip the balance from a small increase in lipid infiltration without detrimental effects on 
health and reproduction to an accumulation of high amounts of TAG that is strongly 
associated with multiple detrimental effects on metabolic functions of the liver, other 
organs, and the immune system. The proposed microarray study hopefully will provide 
additionally suggestions for alternatives for treatment and/or prevention of fatty liver. 
There is still much more to know about interrelationships between fatty liver and other 
tissue systems, especially regarding the immune and reproductive systems. In particular, an 
in-depth study of the effects of fatty liver and glucagon on the immune and reproductive 
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systems is needed to better understand the long-term implications of fatty liver and glucagon 
on the physiology, health, and productivity of cows. 
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